1
|
Yang H, Wen N, Fan C, Wang F, Zhang Y, Cao L, Zhu S, Hao L, Yan D, Wang L, Song Q, Wang M, Song Y, Ma C, An Z, Rodewald LE, Wang H, Yin Z. Thirty Years of Experience of Acute Flaccid Paralysis Surveillance for Polio - China, 1993-2022. China CDC Wkly 2024; 6:344-349. [PMID: 38736467 PMCID: PMC11082049 DOI: 10.46234/ccdcw2024.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2023] [Accepted: 03/26/2024] [Indexed: 05/14/2024] Open
Abstract
Introduction Detecting poliovirus infections proves to be highly challenging due to their asymptomatic nature and infectious potential, highlighting the crucial importance of effective detection methods in the context of polio eradication efforts. In many countries, including China, the primary approach for identifying polio outbreaks has been through acute flaccid paralysis (AFP) surveillance. In this study, we conducted an evaluation spanning three decades (1993-2022) to assess the effectiveness of AFP surveillance in China. Methods Data on all AFP cases identified since 1993 and national-level AFP surveillance system quality indicators aligned with the World Health Organization (WHO) standards were collected for analysis. The quality indicators assess surveillance sensitivity, completeness, timeliness of detection notification, case investigation, and laboratory workup. Surveillance sensitivity is determined by the non-polio AFP (NPAFP) detection rate among children under 15 years of age. Results Between 1993 and 2022, a total of 150,779 AFP cases were identified and reported. Within this pool, surveillance identified 95 cases of wild poliovirus (WPV) and 24 cases due to vaccine-derived poliovirus. From 1995 onwards, the detection rate of NPAFP cases consistently adhered to the WHO and national standards of ≥1 case per 100,000, falling between 1.38 and 2.76. Starting in 1997, all timeliness indicators consistently achieved the criteria of 80%, apart from the consistency in meeting standards set for the rate of positive specimens sent to the national laboratory. Conclusions AFP surveillance has been instrumental in China's accomplishment of maintaining a polio-free status. The ongoing adherence to key performance indicators, ensuring sensitivity and prompt specimen collection, demonstrates that AFP surveillance is proficient in detecting poliovirus in China. As we move into the post-eradication phase, AFP surveillance remains crucial for the sustained absence of polioviruses in the long term.
Collapse
Affiliation(s)
- Hong Yang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ning Wen
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chunxiang Fan
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yong Zhang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Cao
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Shuangli Zhu
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lixin Hao
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dongmei Yan
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Quanwei Song
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Miao Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yifan Song
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chao Ma
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance E. Rodewald
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
2
|
Xia L, Li K, Li Y, An Z, Song Q, Wang L, Yin Z, Wang H. Comparison of Statistical Signal Detection Methods in Adverse Events Following Immunization - China, 2011-2015. China CDC Wkly 2024; 6:350-356. [PMID: 38736468 PMCID: PMC11082050 DOI: 10.46234/ccdcw2024.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 01/24/2024] [Indexed: 05/14/2024] Open
Abstract
Introduction The current study aims to assess the performance of data mining techniques in detecting safety signals for adverse events following immunization (AEFI) using routinely obtained data in China. Four different methods for detecting vaccine safety signals were evaluated. Methods The AEFI data from 2011 to 2015 was collected for our study. We analyzed the data using four different methods to detect signals: the proportional reporting ratio (PRR), reporting odds ratio (ROR), Bayesian confidence propagation neural network (BCPNN), and multi-item gamma Poisson shrinker (MGPS). Each method was evaluated at 1-3 thresholds for positivity. To assess the performance of these methods, we used the published signal rates as gold standards to determine the sensitivity and specificity. Results The number of identified signals varied from 602 for PRR1 (with a threshold of 1) to 127 for MGPS1. When considering the common reactions as the reference standard, the sensitivity ranged from 0.9% for MGPS1/2 to 38.2% for PRR1/2, and the specificity ranged from 85.2% for PRR1 and ROR1 to 96.7% for MGPS1. When considering the rare reactions as the reference standard, PRR1, PRR2, ROR1, ROR2, and BCPNN exhibited the highest sensitivity (73.3%), while MGPS1 exhibited the highest specificity (96.9%). Discussion For common reactions, the sensitivities were modest and the specificities were high. For rare reactions, both the sensitivities and specificities were high. Our study provides valuable insights into the selection of signal detection methods and thresholds for AEFI data in China.
Collapse
Affiliation(s)
- Lanfang Xia
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Keli Li
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Yan Li
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Zhijie An
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Quanwei Song
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Lei Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Zundong Yin
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Huaqing Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| |
Collapse
|
3
|
Song Q, Li Y, Cao L, Hao L, Wen N, Wang F, Ma C, Zhang G, Zheng H, Yu W, An Z, Yin Z, Wang H. Impact of National Immunization Strategies on Vaccine-Preventable Diseases - China, 1950-2021. China CDC Wkly 2024; 6:339-343. [PMID: 38736466 PMCID: PMC11082052 DOI: 10.46234/ccdcw2024.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2024] [Accepted: 03/18/2024] [Indexed: 05/14/2024] Open
Abstract
What is already known about this topic? The incidences of vaccine-preventable diseases (VPDs) included in the Expanded Program on Immunization in China have decreased significantly in recent decades. What is added by this report? This study summarizes the national incidences of nine VPDs and the seroprevalence of hepatitis B surface antigen (HBsAg) under different immunization strategies from 1950 through 2021 in China. The sharpest decreases in VPD incidence and under-5-year HBsAg seroprevalence occurred during the latest stage of the National Immunization Program. The decreases in VPD incidence were most prominent among children under five years of age. What are the implications for public health practice? These findings provide valuable insights for vaccine value assessment and emphasize the importance of implementing immunization strategies in targeted populations.
Collapse
Affiliation(s)
- Quanwei Song
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Yixing Li
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Lei Cao
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Lixin Hao
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Ning Wen
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Fuzhen Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Chao Ma
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Guomin Zhang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Hui Zheng
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Wenzhou Yu
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Zhijie An
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Zundong Yin
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Huaqing Wang
- National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Beijing, China
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| |
Collapse
|
4
|
Zhang YL, Liu XJ, An Z. Effects of Soliton Creation on Transient Transport through a Polymer Chain. J Phys Chem B 2024; 128:1812-1817. [PMID: 38324304 DOI: 10.1021/acs.jpcb.3c08121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2024]
Abstract
By using a nonadiabatic molecular dynamics method combined with the hierarchical equations of motion, we have investigated the nonequilibrium transient transport through a conjugated polymer chain. The polymer chain is described by the Su-Schrieffer-Heeger model, and its two ends are coupled with metal electrodes of different chemical potentials. In order to present the evolutions of the electronic injection and transport in the real-time domain, we have mainly discussed the dynamic relaxation processes of the excited states and transient transport currents. It is found that due to the existence of electron-phonon couplings in the conjugated polymers, creation of solitons not only affects the time of the system achieving the steady state but also leads to periodical oscillations of the steady-state transport currents with time in our simulations. Furthermore, with increasing applied bias voltage, the steady-state transport electronic current increases, which proved that the creation of the solitons can assist the electronic transport. These results have shown that the creation of the excited states is important in understanding the transport properties in organic nanostructures.
Collapse
Affiliation(s)
- Y L Zhang
- Hebei Key Laboratory of Photoelectric Control on Surface and Interface, College of Science, Hebei University of Science and Technology, Shijiazhuang 050018, China
| | - X J Liu
- College of Physics, Hebei Advanced Thin Films Laboratory, Hebei Normal University, Shijiazhuang 050024, China
| | - Z An
- College of Physics, Hebei Advanced Thin Films Laboratory, Hebei Normal University, Shijiazhuang 050024, China
| |
Collapse
|
5
|
Wusiman D, Guo L, Li L, Zhang X, Zhao X, An Z, Huang Z, Zhang Y, Li Z, Ying J, Wei M, Li W, An C. Clinicopathological and prognostic significance of PD-L1 and TIM-3 expression in medullary thyroid carcinoma: a retrospective immunohistochemistry study. J Endocrinol Invest 2024; 47:91-100. [PMID: 37464189 PMCID: PMC10776706 DOI: 10.1007/s40618-023-02126-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/06/2023] [Accepted: 05/30/2023] [Indexed: 07/20/2023]
Abstract
PURPOSE Expression of the programmed death-ligand 1 (PD-L1) and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) in medullary thyroid carcinoma (MTC) has been controversial and rarely reported. METHODS Surgical specimens of 190 MTC patients who had initial curative-intent surgery were collected. Immunohistochemistry of PD-L1 and TIM-3 was performed using 22C3 pharmDx (Dako, Carpinteria, CA) and anti-TIM-3 (1:500, ab241332, Abcam). Stained slides were scored using a combined positive score (CPS) with a cutoff of ≥ 1. We established correlations between PD-L1 expression, TIM-3 expression, clinicopathological, and survival data. RESULTS 13 cases (13/190, 6.84%) were positive for PD-L1 expression, and 42 cases (42/154, 27.27%) for TIM-3 expression. PD-L1 expression was correlated to TIM-3 expression (P = 0.002), but was not related to overall survival (OS) or progression-free survival (PFS). TIM-3 expression was correlated to perineural invasion (P = 0.040). Multivariate Cox analysis showed that lymphovascular invasion (LVI) was independently associated with OS. And tumor size, LVI, and lymph node metastases were significantly associated with PFS. Furthermore, the multivariate logistic analysis showed multifocal status, LVI, pathological T stage and lymph node metastasis were independent risk factors for biochemical recurrence/persistent disease. CONCLUSIONS We demonstrated that PD-L1 and TIM-3 expression were not frequent in MTC and were not associated with survival prognosis. Our results should be considered when clinical trials of PD-L1 or TIM-3 blockades are implemented.
Collapse
Affiliation(s)
- D Wusiman
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - L Guo
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - L Li
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - X Zhang
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - X Zhao
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - Z An
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - Z Huang
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - Y Zhang
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - Z Li
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - J Ying
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
| | - M Wei
- Department of Head and Neck Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 518116, Shenzhen, China.
| | - W Li
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
| | - C An
- Department of Head and Neck Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China.
| |
Collapse
|
6
|
Wang X, Luo L, Wang Y, An Z. Effect of Platelet Function Testing Guidance on Clinical Outcomes for Patients with Intracranial Aneurysms Undergoing Endovascular Treatment. AJNR Am J Neuroradiol 2023; 44:928-933. [PMID: 37414457 PMCID: PMC10411848 DOI: 10.3174/ajnr.a7923] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2023] [Accepted: 06/01/2023] [Indexed: 07/08/2023]
Abstract
BACKGROUND Platelet function testing has been proposed to better adjust individualized antiplatelet treatment for patients undergoing endovascular treatment for intracranial aneurysms. Its clinical significance needs to be comprehensively evaluated. PURPOSE Our aim was to evaluate the impact of platelet function testing-guided versus standard antiplatelet treatment in patients receiving endovascular treatment for intracranial aneurysms. DATA SOURCES PubMed, EMBASE, and the Cochrane Library of clinical trials were searched from inception until March 2023. STUDY SELECTION Eleven studies comprising 6199 patients were included. DATA ANALYSIS ORs with 95% CIs were calculated using random effects models. DATA SYNTHESIS The platelet function testing-guided group was associated with a decreased rate of symptomatic thromboembolic events (OR = 0.57; 95% CI, 0.42-0.76; I2 = 26%). No significant difference was found in asymptomatic thromboembolic events (OR = 1.07; 95% CI, 0.39-2.94; I2 = 48%), hemorrhagic events (OR = 0.71; 95% CI, 0.42-1.19; I2 = 34%), intracranial hemorrhagic events (OR = 0.61; 95% CI, 0.03-10.79; I2 = 62%), morbidity (OR = 0.53; 95% CI, 0.05-5.72; I2 = 86%), and mortality (OR = 1.96; 95% CI, 0.64-5.97; I2 = 0%) between the 2 groups. Subgroup analysis suggested that platelet function testing-guided therapy may contribute to fewer symptomatic thromboembolic events in patients who received stent-assisted coiling (OR = 0.43; 95% CI, 0.18-1.02; I2 = 43%) or a combination of stent-assisted and flow-diverter stent placement (OR = 0.61; 95% CI, 0.36-1.02; I2 = 0%) or who changed from clopidogrel to other thienopyridines (OR = 0.64; 95% CI, 0.40-1.02; I2 = 18%), though the difference did not reach statistical significance. LIMITATIONS Heterogeneous endovascular treatment methods and adjusted antiplatelet regimens were limitations. CONCLUSIONS Platelet function testing-guided antiplatelet strategy significantly reduced the incidence of symptomatic thromboembolic events without any increase in the hemorrhagic events for patients undergoing endovascular treatment for intracranial aneurysms.
Collapse
Affiliation(s)
- X Wang
- From the Departments of Pharmacy (X.W., Z.A.)
| | - L Luo
- Department of Pharmacy (L.L.), Beijing Huairou Hospital, Beijing, China
| | - Y Wang
- Neurosurgery (Y.W.), Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China
| | - Z An
- From the Departments of Pharmacy (X.W., Z.A.)
| |
Collapse
|
7
|
Wang F, Huang B, Deng Y, Zhang S, Liu X, Wang L, Liu Q, Zhao L, Tang L, Wang W, Wang X, Ye F, Hu W, Yang H, Wang S, Ren J, Liu X, Wang C, Guan X, Wang R, Zheng Y, Zhang X, Zheng H, Wu D, An Z, Xu W, Rodewald LE, Gao GF, Yin Z, Tan W. Neutralizing antibody levels associated with injectable and aerosolized Ad5-nCoV boosters and BA.2 infection. BMC Med 2023; 21:233. [PMID: 37400857 DOI: 10.1186/s12916-023-02942-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Accepted: 06/14/2023] [Indexed: 07/05/2023] Open
Abstract
BACKGROUND Several COVID-19 vaccines are in widespread use in China. Few data exist on comparative immunogenicity of different COVID-19 vaccines given as booster doses. We aimed to assess neutralizing antibody levels raised by injectable and inhaled aerosolized recombinant adenovirus type 5 (Ad5)-vectored COVID-19 vaccine as a heterologous booster after an inactivated COVID-19 vaccine two-dose primary series. METHODS Using an open-label prospective cohort design, we recruited 136 individuals who had received inactivated vaccine primary series followed by either injectable or inhaled Ad5-vectored vaccine and measured neutralizing antibody titers against ancestral SARS-CoV-2 virus and Omicron BA.1 and BA.5 variants. We also measured neutralizing antibody levels in convalescent sera from 39 patients who recovered from Omicron BA.2 infection. RESULTS Six months after primary series vaccination, neutralizing immunity against ancestral SARS-CoV-2 was low and neutralizing immunity against Omicron (B.1.1.529) was lower. Boosting with Ad5-vectored vaccines induced a high immune response against ancestral SARS-CoV-2. Neutralizing responses against Omicron BA.5 were ≥ 80% lower than against ancestral SARS-CoV-2 in sera from prime-boost subjects and in convalescent sera from survivors of Omicron BA.2 infection. Inhaled aerosolized Ad5-vectored vaccine was associated with greater neutralizing titers than injectable Ad5-vectored vaccine against ancestral and Omicron SARS-CoV-2 variants. CONCLUSIONS These findings support the current strategy of heterologous boosting with injectable or inhaled Ad5-vectored SARS-CoV-2 vaccination of individuals primed with inactivated COVID-19 vaccine.
Collapse
Affiliation(s)
- Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Baoying Huang
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yao Deng
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Shaobai Zhang
- Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China
| | - Xiaoqiang Liu
- Yunnan Provincial Center for Disease Control and Prevention, Kunming, China
| | - Lei Wang
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, China
| | - Qianqian Liu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Li Zhao
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lin Tang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wenling Wang
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaoqi Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fei Ye
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Weijun Hu
- Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China
| | - Haitao Yang
- Yunnan Provincial Center for Disease Control and Prevention, Kunming, China
| | - Siquan Wang
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, China
| | - Jiao Ren
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaoyu Liu
- Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China
| | - Cangning Wang
- Yunnan Provincial Center for Disease Control and Prevention, Kunming, China
| | - Xuhua Guan
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, China
| | - Ruize Wang
- Shaanxi Provincial Center for Disease Control and Prevention, Xi'an, China
| | - Yan Zheng
- Yunnan Provincial Center for Disease Control and Prevention, Kunming, China
| | - Xianfeng Zhang
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, China
| | - Hui Zheng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wenbo Xu
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lawrence E Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - George F Gao
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Wenjie Tan
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
| |
Collapse
|
8
|
Li Y, Zhang P, An Z, Ma Y, Wang Y, Wang L, Liu Y, Yuan X, Li K, Yin Z, Wang H. Impact of Influenza and Pneumococcal Polysaccharide Vaccination on Economic Burden from Acute Exacerbations of Chronic Obstructive Pulmonary Disease - Hebei Province, China, November 2018 to November 2020. China CDC Wkly 2023; 5:452-458. [PMID: 37274769 PMCID: PMC10236643 DOI: 10.46234/ccdcw2023.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Accepted: 05/06/2023] [Indexed: 06/06/2023] Open
Abstract
What is already known on this topic? Chronic obstructive pulmonary disease (COPD) exacerbations increase household economic burden, but there is limited evidence from prospective cohort studies in China about the impact of vaccination on economic burden. What is added by this report? This study demonstrated the economic burden of COPD exacerbations, pneumonia, and hospitalization in COPD patients in China is substantial. Influenza vaccine and 23-valent pneumococcal polysaccharide vaccine (PPSV23), separately or together, were significantly associated with decreased economic burden. What are the implications for public health practice? Our study supports evidence on recommendations that COPD patients in China are offered both influenza vaccine and PPSV23.
Collapse
Affiliation(s)
- Yan Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Pingshu Zhang
- Kailuan General Hospital, Tangshan City, Hebei Province, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ying Ma
- Kailuan General Hospital, Tangshan City, Hebei Province, China
| | - Yamin Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Liye Wang
- Kailuan General Hospital, Tangshan City, Hebei Province, China
| | - Yunqiu Liu
- Kailuan General Hospital, Tangshan City, Hebei Province, China
| | - Xiaodong Yuan
- Kailuan General Hospital, Tangshan City, Hebei Province, China
| | - Keli Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
9
|
Song Q, Ma C, Hao L, Wang F, An Z, Yin Z, Wang H. Effects of Three Major Immunization Interventions on Measles Control - China, 1952-2021. China CDC Wkly 2023; 5:385-390. [PMID: 37197450 PMCID: PMC10184381 DOI: 10.46234/ccdcw2023.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2023] [Accepted: 04/25/2023] [Indexed: 05/19/2023] Open
Affiliation(s)
- Quanwei Song
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chao Ma
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lixin Hao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- Huaqing Wang,
| |
Collapse
|
10
|
Wu Y, Lv K, Zheng B, Hao X, Lai W, Xia X, Yang G, Huang S, Luo Z, Yang G, Lv C, An Z, Peng W, Song T, Yuan Q. Development and validation of a clinical nomogram predicting detrusor underactivity via symptoms and noninvasive test parameters in men with benign prostatic hyperplasia. Eur Urol 2023. [DOI: 10.1016/s0302-2838(23)00080-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
|
11
|
Yang H, Qi Q, Zhang Y, Wen N, Cao L, Liu Y, Fan C, Yan D, Zhu X, Hao L, Zhu S, Ma Q, Liu J, Ma C, Nan L, Chen Y, Ma X, Chen N, Deng K, Shao G, Ding X, An Z, Rodewald LE, Li X, Wang D, Zhu H, Wang H, Feng Z, Xu W, Zhou J, Yin Z. Analysis of a Sabin-Strain Inactivated Poliovirus Vaccine Response to a Circulating Type 2 Vaccine-Derived Poliovirus Event in Sichuan Province, China 2019-2021. JAMA Netw Open 2023; 6:e2249710. [PMID: 36602797 PMCID: PMC9856606 DOI: 10.1001/jamanetworkopen.2022.49710] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
IMPORTANCE The Sabin-strain inactivated poliovirus vaccine (IPV) may be a tool for polio outbreak response in certain situations. OBJECTIVE To investigate the response to a type 2 vaccine-derived poliovirus (VDPV2) outbreak. DESIGN, SETTING, AND PARTICIPANTS This case series was conducted in China after a VDPV2 was detected in stool specimens from a child with acute flaccid paralysis (AFP) in Sichuan Province in 2019, 3 years after the global withdrawal of live, attenuated type 2 oral poliovirus vaccine (OPV). Investigation followed National Health Commission and World Health Organization guidance and included searching hospitals for unreported AFP cases; testing stool specimens from the child, his contacts, and local children; enhanced environmental surveillance for VDPV2s in wastewater; and measuring vaccination coverage. Sabin-strain IPV campaigns were conducted in a wide geographic area. MAIN OUTCOMES AND MEASURES Any VDPV2 detection after completion of the supplementary immunization activities. RESULTS A 28-nucleotide-change VDPV2 was isolated from a young boy. Three VDPV2s were detected in healthy children; 2 were contacts of the original child, and none had paralysis. A search of 31 million hospital records found 10 unreported AFP cases; none were polio. No type 2 polioviruses were found in wastewater. Prior to the event, polio vaccine coverage was 65% among children younger than 5 years. Sabin-strain IPV campaigns reached more than 97% of targeted children, administering 1.4 million doses. No transmission source was identified. More than 1 year of enhanced poliovirus environmental and AFP surveillance detected no additional VDPVs. CONCLUSIONS AND RELEVANCE These findings suggest that the circulating VPDV2 outbreak in 2019 was associated with low vaccine coverage. An investigation discovered 3 infected but otherwise healthy children and no evidence of the virus in wastewater. Following Sabin-strain IPV-only campaigns expanding from county to prefecture, the poliovirus was not detected, and the outbreak response was considered by an expert panel and the World Health Organization to have been successful. This success suggests that the Sabin-strain IPV may be a useful tool for responding to circulating VDPV2 outbreaks when high-quality supplementary immunization activities can be conducted and carefully monitored in settings with good sanitation.
Collapse
Affiliation(s)
- Hong Yang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qi Qi
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Yong Zhang
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ning Wen
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Cao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yu Liu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Chunxiang Fan
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dongmei Yan
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaoping Zhu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Lixin Hao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Shuangli Zhu
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qianli Ma
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Jiajie Liu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Chao Ma
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Nan
- Liangshan Prefectural Center for Disease Control and Prevention, Liangshan, China
| | - Yong Chen
- Leibo County Center for Disease Control and Prevention, Liangshan, China
| | - Xiaozhen Ma
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Na Chen
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Kun Deng
- Liangshan Prefectural Center for Disease Control and Prevention, Liangshan, China
| | - Ge Shao
- Chinese Field Epidemiology Training Program, Beijing, China
| | - Xianxiang Ding
- Chinese Field Epidemiology Training Program, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance E. Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaolei Li
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dongyan Wang
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zhu
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wenbo Xu
- Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jiushun Zhou
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
12
|
Tang L, Zhang Y, Wang F, Wu D, Qian ZH, Zhang R, Wang AB, Huang C, Wang H, Ye Y, Lu M, Wang C, Ma YT, Pan J, Li YF, Lv XY, An Z, Rodewald L, Wang XY, Shao YM, Wu ZY, Yin Z. Relative vaccine effectiveness against Delta and Omicron COVID-19 after homologous inactivated vaccine boosting: a retrospective cohort study. BMJ Open 2022; 12:e063919. [PMID: 36368753 PMCID: PMC9659710 DOI: 10.1136/bmjopen-2022-063919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
UNLABELLED ObjectiveTwo COVID-19 outbreaks occurred in Henan province in early 2022-one was a Delta variant outbreak and the other was an Omicron variant outbreak. COVID-19 vaccines used at the time of the outbreak were inactivated, 91.8%; protein subunit, 7.5%; and adenovirus5-vectored, 0.7% vaccines. The outbreaks provided an opportunity to evaluate variant-specific breakthrough infection rates and relative protective effectiveness of homologous inactivated COVID-19 vaccine booster doses against symptomatic infection and pneumonia. DESIGN Retrospective cohort study METHODS: We evaluated relative vaccine effectiveness (rVE) with a retrospective cohort study of close contacts of infected individuals using a time-dependent Cox regression model. Demographic and epidemiologic data were obtained from the local Centers for Disease Control and Prevention; clinical and laboratory data were obtained from COVID-19-designated hospitals. Vaccination histories were obtained from the national COVID-19 vaccination dataset. All data were linked by national identification number. RESULTS Among 784 SARS-CoV-2 infections, 379 (48.3%) were caused by Delta and 405 (51.7%) were caused by Omicron, with breakthrough rates of 9.9% and 17.8%, respectively. Breakthrough rates among boosted individuals were 8.1% and 4.9%. Compared with subjects who received primary vaccination series ≥180 days before infection, Cox regression modelling showed that homologous inactivated booster vaccination was statistically significantly associated with protection from symptomatic infection caused by Omicron (rVE 59%; 95% CI 13% to 80%) and pneumonia caused by Delta (rVE 62%; 95% CI 34% to 77%) and Omicron (rVE 87%; 95% CI 3% to 98%). CONCLUSIONS COVID-19 vaccination in China provided good protection against symptomatic COVID-19 and COVID-19 pneumonia caused by Delta and Omicron variants. Protection declined 6 months after primary series vaccination but was restored by homologous inactivated booster doses given 6 months after the primary series.
Collapse
Affiliation(s)
- Lin Tang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yanyang Zhang
- Department of Henan Immunization Program, Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhao-Hui Qian
- NHC Key Laboratory of Systems Biology of Pathogens, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Rui Zhang
- National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology; Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China
| | - Ai-Bin Wang
- Beijing Ditan Hospital Capital Medical University, Beijing, China
| | - Chang Huang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- China Field Epidemiology Training Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Haifeng Wang
- Department of Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Ying Ye
- Department of Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Mingxia Lu
- Department of Henan Immunization Program, Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Changshuang Wang
- Department of Henan Immunization Program, Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Ya-Ting Ma
- Department of Henan Immunization Program, Henan Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Jingjing Pan
- Department of Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Ya-Fei Li
- Department of Communicable Disease Control and Prevention, Henan Provincial Center for Disease Control and Prevention, Zhengzhou, Henan, China
| | - Xiao-Ya Lv
- Development Center for Medicine and Science & Technology, National Health Commission, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xuan-Yi Wang
- Shanghai Institute of Infectious Disease and Biosecurity, Key Laboratory of Medical Molecular Virology of Minstry of Eduation & Ministry of Health, and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai, China
| | - Yi-Ming Shao
- State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhi-Yin Wu
- Development Center for Medicine and Science & Technology, National Health Commission, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
13
|
Gao B, Jiao TY, Li YT, Chen H, Lin WP, An Z, Ru LH, Zhang ZC, Tang XD, Wang XY, Zhang NT, Fang X, Xie DH, Fan YH, Ma L, Zhang X, Bai F, Wang P, Fan YX, Liu G, Huang HX, Wu Q, Zhu YB, Chai JL, Li JQ, Sun LT, Wang S, Cai JW, Li YZ, Su J, Zhang H, Li ZH, Li YJ, Li ET, Chen C, Shen YP, Lian G, Guo B, Li XY, Zhang LY, He JJ, Sheng YD, Chen YJ, Wang LH, Zhang L, Cao FQ, Nan W, Nan WK, Li GX, Song N, Cui BQ, Chen LH, Ma RG, Zhang ZC, Yan SQ, Liao JH, Wang YB, Zeng S, Nan D, Fan QW, Qi NC, Sun WL, Guo XY, Zhang P, Chen YH, Zhou Y, Zhou JF, He JR, Shang CS, Li MC, Kubono S, Liu WP, deBoer RJ, Wiescher M, Pignatari M. Deep Underground Laboratory Measurement of ^{13}C(α,n)^{16}O in the Gamow Windows of the s and i Processes. Phys Rev Lett 2022; 129:132701. [PMID: 36206440 DOI: 10.1103/physrevlett.129.132701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/13/2021] [Revised: 04/01/2022] [Accepted: 06/01/2022] [Indexed: 06/16/2023]
Abstract
The ^{13}C(α,n)^{16}O reaction is the main neutron source for the slow-neutron-capture process in asymptotic giant branch stars and for the intermediate process. Direct measurements at astrophysical energies in above-ground laboratories are hindered by the extremely small cross sections and vast cosmic-ray-induced background. We performed the first consistent direct measurement in the range of E_{c.m.}=0.24 to 1.9 MeV using the accelerators at the China Jinping Underground Laboratory and Sichuan University. Our measurement covers almost the entire intermediate process Gamow window in which the large uncertainty of the previous experiments has been reduced from 60% down to 15%, eliminates the large systematic uncertainty in the extrapolation arising from the inconsistency of existing datasets, and provides a more reliable reaction rate for the studies of the slow-neutron-capture and intermediate processes along with the first direct determination of the alpha strength for the near-threshold state.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | - R J deBoer
- Center for Nuclear Study, University of Tokyo, Wako, Saitama 351-0198, Japan
| | - M Wiescher
- Center for Nuclear Study, University of Tokyo, Wako, Saitama 351-0198, Japan
- Wolfson Fellow of Royal Society, School of Physics and Astronomy, University of Edinburgh, King's Buildings, Edinburgh EH9 3FD, United Kingdom
| | - M Pignatari
- Konkoly Observatory, Research Centre for Astronomy and Earth Sciences (CSFK), Eötvös Loránd Research Network (ELKH), Konkoly Thege Miklós út 15-17, H-1121 Budapest, Hungary
- CSFK, MTA Centre of Excellence, Budapest, Konkoly Thege Miklós út 15-17, Budapest H-1121, Hungary
- E. A. Milne Centre for Astrophysics, Department of Physics and Mathematics, University of Hull, Hull, HU6 7RX, United Kingdom
| |
Collapse
|
14
|
Wang F, Huang B, Lv H, Feng L, Ren W, Wang X, Tang L, Liu Q, Wu D, Zheng H, An Z, Deng Y, Zhao L, Ye F, Wang W, Zhang H, Chang S, Liao Y, Chen F, Rodewald LE, Gao GF, Yin Z, Tan W. Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination. Front Immunol 2022; 13:967051. [PMID: 36159863 PMCID: PMC9501884 DOI: 10.3389/fimmu.2022.967051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2022] [Accepted: 08/22/2022] [Indexed: 11/21/2022] Open
Abstract
Background BBIBP-CorV and CoronaVac inactivated COVID-19 vaccines are widely-used, World Health Organization-emergency-listed vaccines. Understanding antibody level changes over time after vaccination is important for booster dose policies. We evaluated neutralizing antibody (nAb) titers and associated factors for the first 12 months after primary-series vaccination with BBIBP-CorV and CoronaVac. Methods Our study consisted of a set of cross-sectional sero-surveys in Zhejiang and Shanxi provinces, China. In 2021, we enrolled 1,527 consenting 18-59-year-olds who received two doses of BBIBP-CorV or CoronaVac 1, 3, 6, 9, or 12 months earlier and obtained blood samples and demographic and medical data. We obtained 6-month convalescent sera from 62 individuals in Hebei province. Serum nAb titers were measured by standard micro-neutralization cytopathic effect assay in Vero cells with ancestral SARS-CoV-2 strain HB01. We used the first WHO International Standard (IS) for anti-SARS-CoV-2 immunoglobulin (NIBSC code 20/136) to standardized geometric mean concentrations (IU/mL) derived from the nAb geometric mean titers (GMT over 1:4 was considered seropositive). We analyzed nAb titer trends using Chi-square and factors related to nAb titers with logistic regression and linear models. Results Numbers of subjects in each of the five month-groupings ranged from 100 to 200 for each vaccine and met group-specific target sample sizes. Seropositivity rates from BBIBP-CorV were 98.0% at 1 month and 53.5% at 12 months, and GMTs were 25.0 and 4.0. Respective seropositivity rates from CoronaVac were 90.0% and 62.5%, and GMTs were 20.2 and 4.1. One-, three-, six-, nine-, and twelve-month GMCs were 217.2, 84.1, 85.7, 44.6, and 10.9 IU/mL in BBIBP-CorV recipients and 195.7, 94.6, 51.7, 27.6, and 13.4 IU/mL in CoronaVac recipients. Six-month convalescent seropositivity was 95.2%; GMC was 108.9 IU/mL. Seropositivity and GMCs were associated with age, sex, and time since vaccination. Conclusions Neutralizing Ab levels against ancestral SARS-CoV-2 from BBIBP-CorV or CoronaVac vaccination were similar and decreased with increasing time since vaccination; over half of 12-month post-vaccination subjects were seropositive. Seropositivity and GMCs from BBIBP-CorV and CoronaVac six and nine months after vaccination were similar to or slightly lower than in six-month convalescent sera. These real-world data suggest necessity of six-month booster doses.
Collapse
Affiliation(s)
- Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Baoying Huang
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huakun Lv
- Immunization Program Institute, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Lizhong Feng
- Immunization Program Institute, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
| | - Weihong Ren
- Xingtai Center for Disease Control and Prevention, Xingtai, China
| | - Xiaoqi Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lin Tang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qianqian Liu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yao Deng
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Li Zhao
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fei Ye
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wenling Wang
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hangjie Zhang
- Immunization Program Institute, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Shaoying Chang
- Immunization Program Institute, Shanxi Provincial Center for Disease Control and Prevention, Taiyuan, China
| | - Yuting Liao
- School of Public Health, Xiamen University, Xiamen, China
| | - Fengyang Chen
- Xingtai Center for Disease Control and Prevention, Xingtai, China
| | - Lance E. Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - George F. Gao
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- *Correspondence: Zundong Yin, ; Wenjie Tan,
| | - Wenjie Tan
- National Health Commission (NHC) Key Laboratory of Biosafety, Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
- *Correspondence: Zundong Yin, ; Wenjie Tan,
| |
Collapse
|
15
|
Ma C, Li J, Wang N, Wang Y, Song Y, Zeng X, Zheng C, An Z, Rodewald L, Yin Z. Prioritization of Vaccines for Inclusion into China’s Expanded Program on Immunization: Evidence from Experts’ Knowledge and Opinions. Vaccines (Basel) 2022; 10:vaccines10071010. [PMID: 35891174 PMCID: PMC9318118 DOI: 10.3390/vaccines10071010] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Revised: 06/20/2022] [Accepted: 06/21/2022] [Indexed: 02/02/2023] Open
Abstract
Background: Vaccine developers in China have made an increasing number of infectious diseases preventable through vaccination. An appropriate decision-making procedure is necessary for making wise decisions on whether to introduce new vaccines into the Expanded Program on Immunization (EPI). When there are several vaccines that could potentially be considered, a scientifically justifiable mechanism is needed for prioritizing and sequencing vaccines for consideration. Methods: We used a modified Delphi technique (MDT) to develop and refine an indicator system to prioritize vaccines and make policy recommendations concerning their introduction into China’s EPI system. From January through May 2021, thirty-nine experts were recruited and participated in a two-round Delphi survey that was based on a set of candidate indicators obtained through a literature review and reference to the WHO vaccine introduction recommendations. Using the resulting indicator system, we conducted a third consultation with a multi-disciplinary group of experts who scored five program-eligible candidate vaccines to determine prioritization and sequencing for consideration of inclusion into the EPI. Results: Response rates of the thirty-nine experts were 100% and 97.4% across the two rounds. Authority coefficients from rounds one to three were over 0.70, reflecting the high accuracy and reliability of the consultation. Coordination coefficients of importance scores for primary, secondary, and tertiary indicators were 0.486, 0.356, 0.275 in round one, and 0.405, 0.340, and 0.236 in round two. According to the scores from 30 experts using our indicator system, the sequence and scores (1–10 scale, 10 highest) of 5 candidate vaccines were varicella (6.91), meningococcal conjugate AC (6.83), Hib (6.74), influenza (6.56), and EV71 (6.17) vaccines. Conclusions: A modified Delphi technique effectively built a scientific, rational, comprehensive, and systematic indicator system for prioritizing vaccine candidates for consideration of inclusion into the EPI. The rank order will be used by the technical working groups of China’s National Immunization Advisory Committee to sequentially develop and present Evidence-to-Recommendation tables for making policy recommendations.
Collapse
Affiliation(s)
- Chao Ma
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China; (C.M.); (J.L.); (Y.W.); (Y.S.); (Z.A.); (L.R.)
| | - Junhong Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China; (C.M.); (J.L.); (Y.W.); (Y.S.); (Z.A.); (L.R.)
| | - Nan Wang
- Shanghai Municipal Center for Disease Control and Prevention, Shanghai 201204, China;
| | - Yamin Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China; (C.M.); (J.L.); (Y.W.); (Y.S.); (Z.A.); (L.R.)
| | - Yudan Song
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China; (C.M.); (J.L.); (Y.W.); (Y.S.); (Z.A.); (L.R.)
| | - Xiang Zeng
- Zhuhai Center for Disease Control and Prevention, Zhuhai 519000, China;
- Chinese Field Epidemiology Training Program (CFETP), Chinese Center for Disease Control and Prevention, Beijing 100050, China
| | - Canjun Zheng
- Division of Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 100050, China;
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China; (C.M.); (J.L.); (Y.W.); (Y.S.); (Z.A.); (L.R.)
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China; (C.M.); (J.L.); (Y.W.); (Y.S.); (Z.A.); (L.R.)
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 100050, China; (C.M.); (J.L.); (Y.W.); (Y.S.); (Z.A.); (L.R.)
- Correspondence:
| |
Collapse
|
16
|
Li Y, Zhang P, An Z, Yue C, Wang Y, Liu Y, Yuan X, Ma Y, Li K, Yin Z, Wang L, Wang H. Effectiveness of influenza and pneumococcal vaccines on chronic obstructive pulmonary disease exacerbations. Respirology 2022; 27:844-853. [PMID: 35705329 DOI: 10.1111/resp.14309] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2021] [Accepted: 05/16/2022] [Indexed: 11/27/2022]
Abstract
BACKGROUND AND OBJECTIVE Single-study evidence of separate and combined effectiveness of influenza and pneumococcal vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To fill this gap, we studied the effectiveness of trivalent seasonal influenza vaccine (TIV) and 23-valent pneumococcal polysaccharide vaccine (PPSV23), separately and together, at preventing adverse COPD outcomes. METHODS Our study used a self-controlled, before-and-after cohort design to assess the effectiveness of TIV and PPSV23 in COPD patients. Patients were recruited from hospitals in Tangshan City, Hebei Province, China. Subjects self-selected into one of the three vaccination schedules: TIV group, PPSV23 group and TIV&PPSV23 group. We used a physician-completed, medical record-verified questionnaire to obtain data on acute exacerbations of COPD (AECOPD), pneumonia and related hospitalization. Vaccine effectiveness was determined by comparing COPD outcomes before and after vaccination, controlling for potential confounding using Cox regression. RESULTS We recruited 474 COPD patients, of whom 109 received TIV, 69 received PPSV23 and 296 received TIV and PPSV23. Overall effectiveness for preventing AECOPD, pneumonia and related hospitalization were respectively 70%, 59% and 58% in the TIV group; 54%, 53% and 46% in the PPSV23 group; and 72%, 73% and 69% in the TIV&PPSV23 group. The vaccine effectiveness without COVID-19 non-pharmaceutical intervention period were 84%, 77% and 88% in the TIV group; 63%, 74% and 66% in the PPSV23 group; and 82%, 83% and 91% in the TIV&PPSV23 group. CONCLUSION Influenza vaccination and PPSV23 vaccination, separately and together, can effectively reduce the risk of AECOPD, pneumonia and related hospitalization. Effectiveness for preventing AECOPD was the greatest.
Collapse
Affiliation(s)
- Yan Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Pingshu Zhang
- Department of Neurology, Kailuan General Hospital, Tangshan, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chenyan Yue
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yamin Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yunqiu Liu
- Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, Tangshan, China
| | - Xiaodong Yuan
- Department of Neurology, Kailuan General Hospital, Tangshan, China
| | - Ying Ma
- Department of Neurology, Kailuan General Hospital, Tangshan, China
| | - Keli Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Liye Wang
- Department of Respiratory and Critical Care Medicine, Kailuan General Hospital, Tangshan, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
17
|
Li M, Liu Q, Wu D, Tang L, Wang X, Yan T, An Z, Yin Z, Gao GF, Wang F, Zheng H. Association of COVID-19 Vaccination and Clinical Severity of Patients Infected with Delta or Omicron Variants - China, May 21, 2021-February 28, 2022. China CDC Wkly 2022; 4:293-297. [PMID: 35433093 PMCID: PMC9008265 DOI: 10.46234/ccdcw2022.074] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/02/2022] [Accepted: 04/06/2022] [Indexed: 02/05/2023] Open
Abstract
What is already known about this topic? Compared with the international mRNA and adenovirus-vectored coronavirus disease 2019 (COVID-19) vaccines, there is less real-world research data about breakthrough cases in people vaccinated with China-made COVID-19 vaccines. Analyses of clinical outcomes of breakthrough cases will be an important supplement to the clinical trial efficacy and observational effectiveness data of China-made COVID-19 vaccines. What is added by this report? COVID-19 vaccine age-eligible individuals (≥3 years old) who received full primary series and a booster dose of China-made COVID-19 vaccines had good protection from pneumonia caused by Delta variant infection. There was only one serious Delta case in children (unvaccinated), but among adults 18 years and older, there was good protection from serious illness with primary vaccination and booster vaccination. Among people ≥60 years, full vaccination and booster vaccination were associated with protection from pneumonia and risk of serious COVID-19 caused by Omicron variant infection. There were few serious Omicron cases. What are the implications for public health practice? Everyone 3 years and older without contraindications should be fully vaccinated against COVID-19; schedule-eligible adults should receive booster doses. The pace of booster dose administration, especially among the elderly, should be accelerated.
Collapse
Affiliation(s)
- Mingshuang Li
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qianqian Liu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lin Tang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaoqi Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Tingting Yan
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Geroge F Gao
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
18
|
Ma C, Sun W, Tang T, Jia M, Liu Y, Wan Y, Han J, Rodewald L, Li J, Song Y, Wang Y, Wu D, Wang F, Zheng H, Tang L, Gao GF, Yin Z, An Z. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: evidence from an outbreak in Yunnan, China, 2021. Vaccine 2022; 40:2869-2874. [PMID: 35400561 PMCID: PMC8971107 DOI: 10.1016/j.vaccine.2022.03.067] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Revised: 03/25/2022] [Accepted: 03/26/2022] [Indexed: 11/26/2022]
Abstract
Background Methods Findings Interpretation
Collapse
|
19
|
Vicencio JM, Evans R, Green R, An Z, Deng J, Treacy C, Mustapha R, Monypenny J, Costoya C, Lawler K, Ng K, De-Souza K, Coban O, Gomez V, Clancy J, Chen SH, Chalk A, Wong F, Gordon P, Savage C, Gomes C, Pan T, Alfano G, Dolcetti L, Chan JNE, Flores-Borja F, Barber PR, Weitsman G, Sosnowska D, Capone E, Iacobelli S, Hochhauser D, Hartley JA, Parsons M, Arnold JN, Ameer-Beg S, Quezada SA, Yarden Y, Sala G, Ng T. Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans. Cell Death Dis 2022; 13:274. [PMID: 35347108 PMCID: PMC8960767 DOI: 10.1038/s41419-022-04701-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2021] [Revised: 02/07/2022] [Accepted: 03/01/2022] [Indexed: 11/28/2022]
Abstract
Over the past decade, immunotherapy delivered novel treatments for many cancer types. However, lung cancer still leads cancer mortality, and non-small-cell lung carcinoma patients with mutant EGFR cannot benefit from checkpoint inhibitors due to toxicity, relying only on palliative chemotherapy and the third-generation tyrosine kinase inhibitor (TKI) osimertinib. This new drug extends lifespan by 9-months vs. second-generation TKIs, but unfortunately, cancers relapse due to resistance mechanisms and the lack of antitumor immune responses. Here we explored the combination of osimertinib with anti-HER3 monoclonal antibodies and observed that the immune system contributed to eliminate tumor cells in mice and co-culture experiments using bone marrow-derived macrophages and human PBMCs. Osimertinib led to apoptosis of tumors but simultaneously, it triggered inositol-requiring-enzyme (IRE1α)-dependent HER3 upregulation, increased macrophage infiltration, and activated cGAS in cancer cells to produce cGAMP (detected by a lentivirally transduced STING activity biosensor), transactivating STING in macrophages. We sought to target osimertinib-induced HER3 upregulation with monoclonal antibodies, which engaged Fc receptor-dependent tumor elimination by macrophages, and STING agonists enhanced macrophage-mediated tumor elimination further. Thus, by engaging a tumor non-autonomous mechanism involving cGAS-STING and innate immunity, the combination of osimertinib and anti-HER3 antibodies could improve the limited therapeutic and stratification options for advanced stage lung cancer patients with mutant EGFR.
Collapse
Affiliation(s)
- J M Vicencio
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK.
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
| | - R Evans
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - R Green
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - Z An
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - J Deng
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - C Treacy
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - R Mustapha
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - J Monypenny
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - C Costoya
- Cancer Immunology Unit, Cancer Institute, University College London, London, UK
| | - K Lawler
- Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, Cambridge, UK
| | - K Ng
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - K De-Souza
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - O Coban
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - V Gomez
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
| | - J Clancy
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
| | - S H Chen
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
| | - A Chalk
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
| | - F Wong
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - P Gordon
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - C Savage
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - C Gomes
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
| | - T Pan
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - G Alfano
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - L Dolcetti
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - J N E Chan
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - F Flores-Borja
- Centre for Immunobiology and Regenerative Medicine, Barts & The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - P R Barber
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - G Weitsman
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - D Sosnowska
- School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - E Capone
- Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Center for Advanced Studies and Technology (CAST), Chieti, Italy
| | | | - D Hochhauser
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
| | - J A Hartley
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK
| | - M Parsons
- Randall Centre for Cell and Molecular Biophysics, King's College London, London, UK
| | - J N Arnold
- School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - S Ameer-Beg
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK
| | - S A Quezada
- Cancer Immunology Unit, Cancer Institute, University College London, London, UK
| | - Y Yarden
- Department of Biological Regulation, The Weizmann Institute of Science, Rehovot, Israel
| | - G Sala
- Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Center for Advanced Studies and Technology (CAST), Chieti, Italy
| | - T Ng
- Molecular Oncology Group, Cancer Institute, Paul O'Gorman Building, University College London, London, UK.
- Richard Dimbleby Laboratory of Cancer Research, School of Cancer & Pharmaceutical Sciences, King's College London, London, UK.
| |
Collapse
|
20
|
Wu D, Zhang Y, Tang L, Wang F, Ye Y, Ma C, Zheng H, Yu W, Cao L, Song Y, Reyimu A, Zhang X, Wang H, Nie Y, Lu M, Qi M, Li J, Wang R, Yang K, Wang C, Rodewald LE, Gao GF, An Z, Yin Z. Effectiveness of Inactivated COVID-19 Vaccines Against Symptomatic, Pneumonia, and Severe Disease Caused by the Delta Variant: Real World Study and Evidence — China, 2021. China CDC Wkly 2022; 4:57-65. [PMID: 35186369 PMCID: PMC8837442 DOI: 10.46234/ccdcw2022.009] [Citation(s) in RCA: 17] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2021] [Accepted: 01/17/2022] [Indexed: 11/21/2022] Open
Abstract
What is already known about this topic? Effectiveness of China’s 2 inactivated vaccines (BBIBP-CorV and CoronaVac) against pre-Delta severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) variants ranged from 47% to over 90%, depending on the clinical endpoint, and with greater effectiveness against more severe coronavirus disease 2019 (COVID-19). During an outbreak in Guangdong, inactivated vaccine effectiveness (VE) against the Delta variant was 70% for symptomatic infection and 100% for severe COVID-19. However, separate or combined VE estimates for the two inactivated vaccines against Delta are not available. What is added by this report? In an outbreak that started in a hospital, VEs of completed primary vaccination with inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant were 51%, 61%, and 82%. Completed primary vaccination reduced the risk of progressing from mild to moderate or severe COVID-19 by 74%. VE estimates for BBIBP-CorV and CoronaVac or combined vaccination were similar, and partial vaccination was ineffective. What are the implications for public health practice? Completed primary vaccination with either of the 2 inactivated COVID-19 vaccines reduces risk of symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the Delta variant. Completion of the completed primary vaccination with two doses is necessary for protection from Delta.
Collapse
Affiliation(s)
- Dan Wu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yanyang Zhang
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Lin Tang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ying Ye
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Chao Ma
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wenzhou Yu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Cao
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yifan Song
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Abuduwaili Reyimu
- Akesu Prefectural Center for Disease Control and Prevention, Akesu, Xinjiang Uygur Autonomous Region, China
- China Field Epidemiology Training Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaoxiao Zhang
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Haifeng Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yifei Nie
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Mingxia Lu
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Muge Qi
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Jun Li
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Ruolin Wang
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Kaichao Yang
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | - Changshuang Wang
- Henan Provincial Disease Control and Prevention, Zhengzhou, Henan, China
| | | | - Geroge Fu Gao
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
- Zundong Yin,
| | - Zundong Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
- Zhijie An,
| |
Collapse
|
21
|
Abstract
Zijian Feng and colleagues argue that sustained elimination of SARS-CoV-2 in China offers flexibility in covid-19 vaccination policy and discuss the anticipated challenges and systematic monitoring necessary to keep the immunisation component of the response on track
Collapse
Affiliation(s)
- Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - An Pan
- School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- Chinese Preventive Medicine Association, Beijing, China
| |
Collapse
|
22
|
Liu B, Ding W, An Z, Zhu J, Zhang Z, Li L, Lin W. Tritium analysis in zirconium film with BIXS and EBS: Generality test of Al thin film as the β-ray stopping layer in BIXS. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112751] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
23
|
Li Y, Gao F, Wang Y, Li J, Zhang Y, Lv H, Wang S, Yang H, Liu X, Li K, Wang H, Yin Z, Liang Z, An Z, Mao Q, Feng Z. Immunogenicity and safety of inactivated enterovirus A71 vaccines in children aged 6-35 months in China: a non-inferiority, randomised controlled trial. Lancet Reg Health West Pac 2021; 16:100284. [PMID: 34881371 PMCID: PMC8579145 DOI: 10.1016/j.lanwpc.2021.100284] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 07/12/2021] [Revised: 08/18/2021] [Accepted: 09/03/2021] [Indexed: 11/30/2022]
Abstract
BACKGROUND China's three inactivated enterovirus A71 (EV-A71) vaccines are the first and currently world's only EV-A71 vaccines approved by a national regulatory authority and used to prevent EV-A71 associated diseases. The three vaccines vary by vaccine strain, manufacturing cell substrate, and antigen dose, but no head-to-head comparisons of these vaccines have been done. We compared immunogenicity of the vaccines in children 6-35 months old. METHODS We recruited healthy children aged 6-35 months who lived in a study site county into a multicentre, open-label, non-inferiority, three-group, randomised controlled trial that was conducted in five counties in China. Enrolled children were randomly assigned (1:1:1) to receive two doses of one of the three EV-A71 vaccines. The primary outcome was the proportion of children with EV-A71 neutralizing antibody seroconversion 4 weeks after the second dose; a secondary outcome was adverse events in the 4 weeks after each dose. Analyses of immunogenicity included all children who completed the study (per-protocol analysis). Safety analysis included all children completed safety follow-up after at least one. We used a 10% margin to establish non-inferiority. This trial was registered on a World Health Organization platform: Chinese Clinical Trial Registry (ChiCTR1900026663). FINDINGS 1631 children were assessed for eligibility between Nov 4 and Nov 20, 2019. Of 1500 (92%) enrolled children, 500 were assigned to vaccine group A, B, or C; 483 in group A,484 in group B, and 487 in group C completed the study. Before dose one, the seropositive rates in groups A, B, and C were 9.7%, 7.2%, and 7.0%. Four weeks after the second dose, seroconversion rates of groups A, B, and C were 98.8%, 99.4% and 99.8% - mutually non-inferior in all two-group comparisons. There were no serious adverse events in any group and no evidence of a difference among the three groups in the incidence of local adverse event or systemic adverse event. Fever was the most common adverse event. All children with reported adverse events recovered. INTERPRETATION Non-inferior and high seroconversion rates and equivalent safety of three EV-A71 vaccines supports use any of these vaccines to prevent EV-A71-associated diseases. These results may be useful for regulators, vaccine policy makers, and immunization programmes in China and in countries where EV-A71 is endemic.
Collapse
Affiliation(s)
- Yan Li
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fan Gao
- National Institutes for Food and Drug Control, Beijing, China
| | - Yamin Wang
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jing Li
- Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, Hebei, China
| | - Yuxi Zhang
- Baoding prefectural Center for Disease Control and Prevention, Baoding, China
| | - Huakun Lv
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Shenyu Wang
- Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Haitao Yang
- Yunnan Provincial Center for Disease Control and Prevention, Kunming, China
| | - Xiaoqiang Liu
- Yunnan Provincial Center for Disease Control and Prevention, Kunming, China
| | - Keli Li
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhenglun Liang
- National Institutes for Food and Drug Control, Beijing, China
| | - Zhijie An
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qunying Mao
- National Institutes for Food and Drug Control, Beijing, China
| | - Zijian Feng
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
24
|
Wang M, Liu Y, Yan T, Rodewald L, An Z, Yin Z. Senior Research Scholars in China CDC's National Immunization Program. China CDC Wkly 2021; 3:911-913. [PMID: 34745690 PMCID: PMC8563331 DOI: 10.46234/ccdcw2021.223] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2021] [Accepted: 10/07/2021] [Indexed: 11/14/2022] Open
Affiliation(s)
- Miao Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yanmin Liu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Tingting Yan
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
25
|
Li Y, Ma Y, An Z, Yue C, Wang Y, Liu Y, Yuan X, Zhang S, Shao M, Li C, Li K, Yin Z, Wang L, Wang H. Immunogenicity of trivalent seasonal influenza vaccine in patients with chronic obstructive pulmonary disease. Hum Vaccin Immunother 2021; 17:3131-3136. [PMID: 33984257 PMCID: PMC8381819 DOI: 10.1080/21645515.2021.1911515] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2021] [Revised: 02/26/2021] [Accepted: 03/30/2021] [Indexed: 10/21/2022] Open
Abstract
Objective: Current evidence on the immunogenicity of influenza vaccination in patients with chronic obstructive pulmonary disease (COPD) is limited. To address this need for additional knowledge, we conducted a study on the immunogenicity of trivalent seasonal influenza vaccine (TIV) in COPD patients.Methods: We recruited patients from respiratory outpatient clinics of three hospitals in Tangshan, Hebei province who had stable confirmed COPD, were less than 80 y old, and reported not having had influenza or receiving TIV during the study season prior to enrollment. Patients who had a history of allergy to any TIV component or were classified as having very severe COPD were excluded from the study. Eligible and consenting participants were given one dose of TIV after obtaining a baseline blood sample. A second blood sample was obtained 5 weeks later. We used hemagglutination inhibition (HI) assays to measure antibody responses. We considered seropositive to be an HI titer ≥1:10. We considered seroprotection to be an HI titer ≥1:40 and seroconversion to be either a change from seronegative to a post-vaccination titer of ≥1:40 or a fourfold rise in antibody titer among baseline seropositive subjects. Each subject was followed for 1 month to assess the frequency and type of adverse events.Results: Eighty-eight subjects completed our study; the median age was 64 y; most (62.5%) had moderately severe COPD; 48.9% of the subjects had comorbid conditions in addition to COPD. Post-vaccination seropositive rates for influenza H1N1, H3N2, and B were all 100%; corresponding seroprotection rates were 96.6%, 93.2%, and 98.9%; seroconversion rates were 81.8%, 87.5%, and 75.0%. There were no statistical differences in seroconversion (P = .10) and seroprotection (P = .30) among the three types of influenza virus. Geometric mean titers (1:) of HI antibodies to H1N1, H3N2, and B were 18.8 (95% CI: 14.0-25.1), 12.2 (95% CI: 9.6-15.4), and 31.8 (95% CI: 26.1-38.8) at baseline, and 267.0 (95% CI: 213.8-333.4), 190.3 (95% CI: 151.7-238.6), and 201.1 (95% CI: 166.5-242.8) after vaccination.Conclusion: The immunogenicity of one dose of influenza vaccine was excellent in COPD patients. Our study supports recommending influenza vaccination for COPD patients to provide protection from influenza and its complications.
Collapse
Affiliation(s)
- Yan Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ying Ma
- Respiratory and Neurological Department, Kailuan General Hospital, Tangshan, Hebei, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chenyan Yue
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yamin Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yunqiu Liu
- Respiratory and Neurological Department, Kailuan General Hospital, Tangshan, Hebei, China
| | - Xiaodong Yuan
- Respiratory and Neurological Department, Kailuan General Hospital, Tangshan, Hebei, China
| | - Shuping Zhang
- Respiratory and Neurological Department, Kailuan General Hospital, Tangshan, Hebei, China
| | - Ming Shao
- Department for Biological Products Control, National Institute for Food and Drug Control, Beijing, China
| | - Changgui Li
- Department for Biological Products Control, National Institute for Food and Drug Control, Beijing, China
| | - Keli Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Liye Wang
- Respiratory and Neurological Department, Kailuan General Hospital, Tangshan, Hebei, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
26
|
Wang F, An Z, Rodewald L, Wu D, Tang L, Zheng H, Liu Q, Gao GF, Yin Z. Guangdong's Study of the Effectiveness of China's Inactivated Vaccines Against the SARS-CoV-2 B.1.617.2 (Delta) Variant. China CDC Wkly 2021; 3:728-730. [PMID: 34594978 PMCID: PMC8392787 DOI: 10.46234/ccdcw2021.179] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2021] [Accepted: 08/16/2021] [Indexed: 12/28/2022] Open
Affiliation(s)
- Fuzhen Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lin Tang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qianqian Liu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - George F. Gao
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
27
|
Zeng Y, He H, Wang X, Zhang M, An Z. Climate and air pollution exposure are associated with thyroid function parameters: a retrospective cross-sectional study. J Endocrinol Invest 2021; 44:1515-1523. [PMID: 33159683 DOI: 10.1007/s40618-020-01461-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/19/2020] [Accepted: 10/26/2020] [Indexed: 02/05/2023]
Abstract
OBJECTIVES There are still controversies about the impact of climatic and environmental factors on thyroid function parameters in healthy populations. We investigated the relationships between climate, air pollution exposure, and thyroid function fluctuations. METHODS We retrospectively reviewed 327,913 individuals attending routine health checks from December 2013 to December 2018. We analyzed the associations between thyroid function and climatic factors using Spearman's correlation analysis. We explored the relationships between thyroid function and air pollution exposure using multiple linear regression analysis, after adjusting for age, sex, season, and outdoor temperature. We also performed subgroup analyses by age and sex and sensitivity analyses of different anti-thyroid peroxidase antibody status. RESULTS Thyroid-stimulating hormone (TSH) and free triiodothyronine (FT3) were negatively associated with outdoor temperature (r = - 0.66, P < 0.001; r = - 0.55, P < 0.001), while free thyroxine (FT4) and FT4/FT3 were positively associated with temperature (r = 0.35, P < 0.001; r = 0.79, P < 0.001). An increase of 10 μg/m3 in fine particulate matter ≤ 2.5 μm (PM2.5) was associated with a decrease of 0.12 pmol/L in FT4 and an increase of 0.07 pmol/L in FT3 (both P < 0.01). FT4/FT3 was significantly negatively associated with PM2.5 (coefficient: - 0.06, P < 0.01). These results remained robust in hierarchical analyses and sensitivity analyses. CONCLUSIONS Thyroid function parameters are associated with climate and air pollution exposure. These factors may influence variations in thyroid function. Our results also highlight the importance of public health interventions to reduce air pollution.
Collapse
Affiliation(s)
- Y Zeng
- Department of Laboratory Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, China
| | - H He
- Department of Laboratory Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, China
| | - X Wang
- Department of Laboratory Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, China
| | - M Zhang
- Department of Laboratory Medicine, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, China.
| | - Z An
- Department of Endocrine and Metabolism, West China Hospital, Sichuan University, No. 37, Guoxue Lane, Chengdu, China.
| |
Collapse
|
28
|
Ning XP, An Z, Qiao F, Cai CL, Han L, Song ZG, Li BL, Zhou GW, Wang J, Xu ZY, Lu FL. [Safety and efficacy of transcatheter tricuspid valve replacement with LuX-Valve in patients with severe tricuspid regurgitation]. Zhonghua Xin Xue Guan Bing Za Zhi 2021; 49:455-460. [PMID: 34034378 DOI: 10.3760/cma.j.cn112148-20210125-00091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objectives: To evaluate the safety and efficacy of LuX-Valve on the treatment of severe tricuspid regurgitation (TR). Methods: This is a prospective observational study. From September 2018 to March 2019, 12 patients with severe TR, who were not suitable for surgery, received LuX-Valve implantation in Changhai Hospital. LuX-Valve was implanted under general anesthesia and the guidance of transesophageal echocardiography and X-ray fluoroscopy. Access to the tricuspid valve was achieved via a minimally invasive thoracotomy and transatrial approach. Main endpoints were surgery success and device success. Surgery success was defined as successful implanting the device and withdrawing the delivery system, positioning the valve correctly and stably without severe or life-threatening adverse events. Device success was defined as satisfied valve function (TR severity reduction ≥ 2 grades, tricuspid gradient ≤ 6 mmHg (1 mmHg=0.133 kPa)), absence of malposition, valve failure and reintervention, major adverse events including device related mortality, embolization, conduction system disturbances and new onset shunt across ventricular septum at day 30 post implantation. Results: A total of 12 patients with severe to torrential TR were included in this study. The age was (68.5±6.9) years and 7 were female. All patients had typical right heart failure symptoms. Procedural success was achieved in all cases, there was no intraprocedural mortality or transfer to open surgery. TR significantly improved after LuX-Valve implantation (none/trivial in 8 patients, mild in 3 patients and moderate in 1 patient). The average device time was (9.2±4.2) minutes. Intensive care unit duration was 3.0 (2.0, 4.8) days. One patient died at postoperative day 18 due to non-surgery and device reasons. Transthoracic echocardiography at 30 days after operation showed that TR was significantly reduced (none/trivial in 8 patients, mild in 2 patients and moderate in 1 patient) and device success was achieved in 11 cases. All survived patients experienced a significant improvement in life quality with significantly improvement in New York Heart Association (NYHA) classification (Ⅰ and Ⅱ: 6/11 post operation vs. 0/11 before operation, P=0.012) and there were no device related complications in this patient cohort. Conclusions: LuX-Valve implantation is feasible, safe and effective for the treatment of patients with severe TR.
Collapse
Affiliation(s)
- X P Ning
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - Z An
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - F Qiao
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - C L Cai
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - L Han
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - Z G Song
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - B L Li
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - G W Zhou
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - J Wang
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - Z Y Xu
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| | - F L Lu
- Department of Cardiovascular Surgery, Changhai Hospital, Naval Medical University, Shanghai 200433, China
| |
Collapse
|
29
|
Wang Y, Xu Q, Jeyaseelan V, Ying Z, Mach O, Sutter R, Wen N, Rodewald L, Li C, Wang J, Yuan H, Yin Z, Feng Z, Xu A, An Z. Immunogenicity of two-dose and three-dose vaccination schedules with Sabin inactivated poliovirus vaccine in China: An open-label, randomized, controlled trial. Lancet Reg Health West Pac 2021; 10:100133. [PMID: 34327346 PMCID: PMC8315596 DOI: 10.1016/j.lanwpc.2021.100133] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/03/2020] [Revised: 02/22/2021] [Accepted: 03/04/2021] [Indexed: 11/24/2022]
Abstract
BACKGROUND We assessed immunogenicity of three-dose and two-dose immunization schedules with a Sabin-strain inactivated poliovirus vaccine (sIPV) produced by one Chinese vaccine manufacturer. METHODS This was an open label, randomized, controlled trial conducted in 16 vaccination clinics in Shandong province. Infants were allocated randomly to either a 3-dose study arm (sIPV administered at 2, 3, and 4 months of age) or a 2-dose arm (sIPV administered at 4 and 8-11 months of age). Poliovirus neutralizing antibodies were measured in sera collected prior to the first sIPV dose and one month after the last dose. FINDINGS We enrolled 560 infants; 536 (95.7%) completed the study. Final seropositivity rates were >98% for all three serotypes in both study arms. There were no statistically significant differences in seropositivity between the 2-dose and the 3-dose schedule. Final median reciprocal titres of polio antibodies were high overall (>1:768 for all serotypes) and statistically significantly higher in 2-dose recipients compared with 3-dose recipients (p < 0.001). INTERPRETATION This study offers evidence that two doses of sIPV administered at 4 and 8-11 months of age and three doses of sIPV administered at 2, 3, and 4 months of age both provide serological protection against poliomyelitis. Median reciprocal titres of polio antibodies were high overall, and were more related to the interval between doses than the number of doses, with the longer interval of the 2-dose schedule producing higher reciprocal titres than the shorter-interval 3-dose schedule. The protection provided by the 3-dose schedule is achieved earlier in life than the protection with the 2-dose schedule. Countries planning to use an IPV-only schedule in the post-eradication era can consider this 2-dose sIPV option as an immunogenic and dose-sparing strategy. FUNDING World Health Organization (from a grant from International PolioPlus Committee, Rotary International, Evanston, IL, USA).
Collapse
Affiliation(s)
- Yamin Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qing Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Vishali Jeyaseelan
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Zhifang Ying
- National Institutes for Food and Drug Control, Beijing, China
| | - Ondrej Mach
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Roland Sutter
- Polio Eradication Department, World Health Organization, Geneva, Switzerland
| | - Ning Wen
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Changgui Li
- National Institutes for Food and Drug Control, Beijing, China
| | - Jie Wang
- Dezhou prefecture-level Center for Disease Control and Prevention, Dezhou, Shandong, China
| | - Hui Yuan
- Liaocheng prefecture-level Center for Disease Control and Prevention, Liaocheng, Shandong, China
| | - Zundong Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Aiqiang Xu
- Shandong Provincial Center for Disease Control and Prevention, Jinan, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
30
|
Li Y, Ma Y, An Z, Yue C, Wang Y, Wang L, Liu Y, Yuan X, Zhang S, Ye Q, Li H, Li K, Yin Z, Wang H. Immunogenicity of 23-Valent Pneumococcal Polysaccharide Vaccine in Patients with Chronic Obstructive Pulmonary Disease - Hebei Province, China, September-December, 2019. China CDC Wkly 2021; 3:331-334. [PMID: 34594878 PMCID: PMC8393071 DOI: 10.46234/ccdcw2021.089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Accepted: 04/08/2021] [Indexed: 11/14/2022] Open
Abstract
What is already known on this topic? The global burden of chronic obstructive pulmonary disease (COPD) is serious. Pneumococcal infection is associated with acute exacerbations of COPD (AECOPD). The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for COPD patients to decrease AECOPD due to pneumococcus, but evidence on the immunogenicity of PPSV23 in COPD patients is limited. What is added by this report? This study showed good immunogenicity of one dose of PPSV23 in COPD patients. Antibody levels against all 23 vaccine serotypes were assessed before and four weeks after vaccination of COPD patients with one dose of PPSV23. The percent of COPD patients who had two-fold increases in pneumococcal antibody levels following vaccination ranged from 65.2% (serotype 3) to 94.4% (serotype 2). There were statistically significant differences in immunogenicity by serotype. What are the implications for public health practice? This study supports current recommendations for PPSV23 vaccination of COPD patients in China to provide protection from pneumococcal diseases.
Collapse
Affiliation(s)
- Yan Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ying Ma
- Kailuan General Hospital, Tangshan, Hebei, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chenyan Yue
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yamin Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Liye Wang
- Kailuan General Hospital, Tangshan, Hebei, China
| | - Yunqiu Liu
- Kailuan General Hospital, Tangshan, Hebei, China
| | | | | | - Qiang Ye
- National Institute for Food and Drug Control, Beijing, China
| | - Hong Li
- National Institute for Food and Drug Control, Beijing, China
| | - Keli Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
31
|
Li Z, Guan X, Mao N, Luo H, Qin Y, He N, Zhu Z, Yu J, Li Y, Liu J, An Z, Gao W, Wang X, Sun X, Song T, Yang X, Wu M, Wu X, Yao W, Peng Z, Sun J, Wang L, Guo Q, Xiang N, Liu J, Zhang B, Su X, Rodewald L, Li L, Xu W, Shen H, Feng Z, Gao GF. Antibody seroprevalence in the epicenter Wuhan, Hubei, and six selected provinces after containment of the first epidemic wave of COVID-19 in China. Lancet Reg Health West Pac 2021; 8:100094. [PMID: 33585828 PMCID: PMC7864613 DOI: 10.1016/j.lanwpc.2021.100094] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 12/17/2020] [Accepted: 01/11/2021] [Indexed: 12/21/2022]
Abstract
BACKGROUND China implemented containment measures to stop SARS-CoV-2 transmission in response to the COVID-19 epidemic. After the first epidemic wave, we conducted population-based serological surveys to determine extent of infection, risk factors for infection, and neutralization antibody levels to assess the real infections in the random sampled population. METHODS We used a multistage, stratified cluster random sampling strategy to conduct serological surveys in three areas - Wuhan, Hubei Province outside Wuhan, and six provinces selected on COVID-19 incidence and containment strategy. Participants were consenting individuals >1 year old who resided in the survey area >14 days during the epidemic. Provinces screened sera for SARS-CoV-2-specific IgM, IgG, and total antibody by two lateral flow immunoassays and one magnetic chemiluminescence enzyme immunoassay; positive samples were verified by micro-neutralization assay. FINDINGS We enrolled 34,857 participants (overall response rate, 92%); 427 were positive by micro-neutralization assay. Wuhan had the highest weighted seroprevalence (4•43%, 95% confidence interval [95%CI]=3•48%-5•62%), followed by Hubei-ex-Wuhan (0•44%, 95%CI=0•26%-0•76%), and the other provinces (<0•1%). Living in Wuhan (adjusted odds ratio aOR=13•70, 95%CI= 7•91-23•75), contact with COVID-19 patients (aOR=7•35, 95%CI=5•05-10•69), and age over 40 (aOR=1•36, 95%CI=1•07-1•72) were significantly associated with SARS-CoV-2 infection. Among seropositives, 101 (24%) reported symptoms and had higher geometric mean neutralizing antibody titers than among the 326 (76%) without symptoms (30±2•4 vs 15±2•1, p<0•001). INTERPRETATION The low overall extent of infection and steep gradient of seropositivity from Wuhan to the outer provinces provide evidence supporting the success of containment of the first wave of COVID-19 in China. SARS-CoV-2 infection was largely asymptomatic, emphasizing the importance of active case finding and physical distancing. Virtually the entire population of China remains susceptible to SARS-CoV-2; vaccination will be needed for long-term protection. FUNDING This study was supported by the Ministry of Science and Technology (2020YFC0846900) and the National Natural Science Foundation of China (82041026, 82041027, 82041028, 82041029, 82041030, 82041032, 82041033).
Collapse
Affiliation(s)
- Zhongjie Li
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Xuhua Guan
- Hubei Provincial Center for Disease Control and Prevention, Wuhan, Hubei, China
| | - Naiying Mao
- National Institute for Viral Disease Control and Prevention (China CDC), Beijing, China
| | - Huiming Luo
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Ying Qin
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Na He
- Fudan University, Shanghai, China
| | - Zhen Zhu
- National Institute for Viral Disease Control and Prevention (China CDC), Beijing, China
| | - Jianxing Yu
- National Institute for Communicable Disease Control and Prevention (China CDC), Beijing, China
| | - Yu Li
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Jianhua Liu
- Guangzhou Municipal Center for Disease Control and Prevention, Guangzhou, Guangdong, China
| | - Zhijie An
- National Immunization Programme (China CDC), Beijing, China
| | - Wenjing Gao
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China
| | - Xiaoli Wang
- Beijing Center for Disease Control and Prevention, Beijing, China
| | - Xiaodong Sun
- Shanghai Center for Disease Control and Prevention, Shanghai, China
| | - Tie Song
- Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, Guangdong, China
| | - Xingfen Yang
- School of Public Health, Southern Medical University, Guangzhou, Guangdong, China
| | - Ming Wu
- Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, Jiangsu, China
| | - Xianping Wu
- Sichuan Provincial Center for Disease Control and Prevention, Chengdu, Sichuan, China
| | - Wenqing Yao
- Liaoning Provincial Center for Disease Control and Prevention, Shenyang, Liaoning, China
| | - Zhibin Peng
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Junling Sun
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Liping Wang
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Qing Guo
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Nijuan Xiang
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Jun Liu
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Bike Zhang
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Xuemei Su
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
- Beijing Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - Liming Li
- Peking University Center for Public Health and Epidemic Preparedness & Response
- Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, China
| | - Wenbo Xu
- National Institute for Viral Disease Control and Prevention (China CDC), Beijing, China
| | - Hongbing Shen
- Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| | - George F Gao
- Chinese Center for Disease Control and Prevention (China CDC), Beijing, China
| |
Collapse
|
32
|
Yang X, Zhao H, Li Z, Zhu A, Ren M, Geng M, Li Y, Qin Y, Feng L, Peng Z, An Z, Zheng J, Li Z, Feng Z. Influenza Vaccine Effectiveness in Mainland China: A Systematic Review and Meta-Analysis. Vaccines (Basel) 2021; 9:vaccines9020079. [PMID: 33498688 PMCID: PMC7912587 DOI: 10.3390/vaccines9020079] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2020] [Revised: 01/20/2021] [Accepted: 01/20/2021] [Indexed: 12/03/2022] Open
Abstract
Influenza endangers human health but can be prevented in part by vaccination. Assessing influenza vaccine effectiveness (VE) provides scientific evidence for developing influenza vaccination policy. We conducted a systematic review and meta-analysis of studies that evaluated influenza VE in mainland China. We searched six relevant databases as of 30 August 2019 to identify studies and used Review Manager 5.3 software to analyze the included studies. The Newcastle–Ottawa scale was used to assess the risk of publication bias. We identified 1408 publications, and after removing duplicates and screening full texts, we included 21 studies in the analyses. Studies were conducted in Beijing, Guangzhou, Suzhou, and Zhejiang province from the 2010/11 influenza season through the 2017/18 influenza season. Overall influenza VE for laboratory confirmed influenza was 36% (95% CI: 25–46%). In the subgroup analysis, VE was 45% (95% CI: 18–64%) for children 6–35 months who received one dose of influenza vaccine, and 57% (95% CI: 50–64%) who received two doses. VE was 47% (95% CI: 39–54%) for children 6 months to 8 years, and 18% (95% CI: 0–33%) for adults ≥60 years. For inpatients, VE was 21% (95% CI: −11–44%). We conclude that influenza vaccines that were used in mainland China had a moderate effectiveness, with VE being higher among children than the elderly. Influenza VE should be continuously monitored in mainland China to provide evidence for policy making and improving uptake of the influenza vaccine.
Collapse
Affiliation(s)
- Xiaokun Yang
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Hongting Zhao
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Zhili Li
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Aiqin Zhu
- Division of Infectious Disease Prevention and Disinfection Management, Shanghai Pudong New Area Center for Disease Control and Prevention, Shanghai 200136, China;
| | - Minrui Ren
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Mengjie Geng
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Yu Li
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Ying Qin
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Luzhao Feng
- School of Population Medicine and Public Health, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China;
| | - Zhibin Peng
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing 102206, China;
| | - Jiandong Zheng
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
- Correspondence: (J.Z.); (Z.L.); (Z.F.); Tel.: +86-010-5890-0541 (J.Z.); +86-010-5890-0543 (Z.L.); +86-010-5890-0309 (Z.F.)
| | - Zhongjie Li
- Division of Infectious Disease, Key Laboratory of Surveillance and Early-Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China; (X.Y.); (H.Z.); (Z.L.); (M.R.); (M.G.); (Y.L.); (Y.Q.); (Z.P.)
- Correspondence: (J.Z.); (Z.L.); (Z.F.); Tel.: +86-010-5890-0541 (J.Z.); +86-010-5890-0543 (Z.L.); +86-010-5890-0309 (Z.F.)
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing 102206, China
- Correspondence: (J.Z.); (Z.L.); (Z.F.); Tel.: +86-010-5890-0541 (J.Z.); +86-010-5890-0543 (Z.L.); +86-010-5890-0309 (Z.F.)
| |
Collapse
|
33
|
Liu Y, Xu Y, Wang J, Che X, Gu W, Du J, Zhang X, Zhang X, Jiang W, Chen J, An Z. Vaccination pattern of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in Hangzhou, China: a coverage and adverse events following immunization of different age groups. Hum Vaccin Immunother 2021; 17:157-161. [PMID: 32530728 PMCID: PMC7872049 DOI: 10.1080/21645515.2020.1765620] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2020] [Accepted: 04/30/2020] [Indexed: 01/31/2023] Open
Abstract
Background: 23-valent pneumococcal polysaccharide vaccine (PPSV23) has been used to prevent pneumococcal disease, and PPSV23 became available in 2003 in Hangzhou, China as a private-sector, vaccinee-chosen vaccine. No national guidelines for PPSV23 have been developed. We analyzed PPSV23 coverage and utilization in Hangzhou to determine patterns of PPSV23 use and the occurrence of adverse events following immunization (AEFI) in Hangzhou. Materials and Methods: Individuals over 2 years of age in Hangzhou were included. Vaccination data during 2006-2017 was retrieved from Hangzhou's Immunization Information System (HZIIS). We used descriptive epidemiological methods to determine PPSV23 usage patterns and AEFI occurrence. Results: In 2017, there were 9,027,973 persons above 2 years of age with the coverage of PPSV23 of 2.98%. The coverage of PPSV23 among elders ranged from 0.17% to 0.69%, and the overall coverage was higher in urban areas (3.70%) than in rural (3.34%) and suburban areas (2.16%). 93.45% of 268957 recipients were vaccinated with PPSV23 at 2-4 years of age. 394 AEFI of PPSV23 cases were reported to the Chinese national adverse event following immunization information system (CNAEFIS) during 2008-2017, with the reporting rate of 140.39 per 100,000 doses. Conclusion: Persons in Hangzhou had overall low PPSV23 vaccination coverage especially for adults. Most of PPSV23 were used in children, while the proportion of the old population over 60 years slightly increased over year. PPSV23 was safe with a low reported AEFI rate, which was a little higher for children than for the elderly (over 60 years).
Collapse
Affiliation(s)
- Yan Liu
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Yuyang Xu
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Jun Wang
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Xinren Che
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Wenwen Gu
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Jian Du
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Xiaoping Zhang
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Xuechao Zhang
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Wei Jiang
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Junfang Chen
- Department of Expanded Program on Immunization, Hangzhou Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Zhijie An
- Department of National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
34
|
Wen N, Su Q, Fan C, Wang H, Zhang Y, Cao L, Xia W, An Z, Luo H. Cases of Residual Paralysis in an Acute Flaccid Paralysis Surveillance System - China, 2001-2010. China CDC Wkly 2020; 2:962-967. [PMID: 34594815 PMCID: PMC8422187 DOI: 10.46234/ccdcw2020.261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 12/10/2020] [Indexed: 12/02/2022] Open
Affiliation(s)
- Ning Wen
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qiru Su
- Chinese Center for Disease Control and Prevention, Beijing, China.,Shenzhen Children's hospital, Shenzhen, Guangdong, China
| | - Chunxiang Fan
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Haibo Wang
- Chinese Center for Disease Control and Prevention, Beijing, China.,Clinical Research Institute, Peking University, Beijing, China
| | - Yong Zhang
- National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Cao
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wei Xia
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huiming Luo
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
35
|
Wu J, Yu W, Cao L, Cao L, Rodewald L, Ye J, Song Y, Li L, Liu X, Wen N, Wang F, Hao L, Li Y, Zheng H, Li K, Ma C, Wu D, Liu Y, Zhang G, An Z, Wang H, Yin Z. Effectiveness of Catch-Up Vaccinations after COVID-19 Containment - China, 2020. China CDC Wkly 2020; 2:968-974. [PMID: 34594816 PMCID: PMC8422188 DOI: 10.46234/ccdcw2020.262] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2020] [Accepted: 12/09/2020] [Indexed: 12/29/2022] Open
Affiliation(s)
- Jing Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- Jiangxi Provincial Center for Disease Control and Prevention, Nanchang, Jiangxi, China
| | - Wenzhou Yu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Cao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lingsheng Cao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jiakai Ye
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yifan Song
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Li Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaoxue Liu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ning Wen
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lixin Hao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yixing Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Keli Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chao Ma
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yanmin Liu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Guomin Zhang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
36
|
Wang X, Sun L, He N, An Z, Yu R, Li C, Li Y, Li Y, Liu X, Fang X, Zhao J. Increased expression of CXCL2 in ACPA-positive rheumatoid arthritis and its role in osteoclastogenesis. Clin Exp Immunol 2020; 203:194-208. [PMID: 33010041 DOI: 10.1111/cei.13527] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 08/29/2020] [Accepted: 09/13/2020] [Indexed: 12/16/2022] Open
Abstract
Anti-citrullinated protein/peptide antibodies (ACPA) play important roles in the pathogenesis of rheumatoid arthritis (RA). ACPA-positive (ACPA+ ) and ACPA-negative (ACPA- ) RA were suggested to be different disease subsets, with distinct differences in genetic variation and clinical outcomes. The aims of the present study were to compare gene expression profiles in ACPA+ and ACPA- RA, and to identify novel candidate gene signatures that might serve as therapeutic targets. Comprehensive transcriptome analysis of peripheral blood mononuclear cells (PBMCs) from ACPA+ and ACPA- RA patients and healthy controls was performed via RNA sequencing. A validation cohort was used to further investigate differentially expressed genes via polymerase chain reaction (PCR) and enzyme-linked immunosorbent assay (ELISA). Spearman's correlation test was used to evaluate the correlation of differentially expressed genes and the clinical and laboratory data of the patients. The role of differentially expressed genes in osteoclastogenesis was further investigated. Expression of C-X-C motif chemokine ligand 2 (CXCL2) was significantly increased in ACPA+ RA than in ACPA- RA, which was validated in PBMCs and serum. CXCL2 promoted the migration of CD14+ monocytes and increased osteoclastogenesis in RA patients. RAW264.7 macrophages were used to investigate specific mechanisms, and the results suggested that CXCL2 stimulated osteoclastogenesis via extracellular receptor kinase (ERK) mitogen-activated protein kinase (MAPK) and nuclear factor kappa B pathways. In conclusion, CXCL2 was highly expressed in ACPA+ RA than in ACPA- RA. CXCL2 promoted osteoclastogenesis and was related to bone erosion in RA, which suggests that the blockade of CXCL2 might be a novel strategy for the treatment of RA.
Collapse
Affiliation(s)
- X Wang
- Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
| | - L Sun
- Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
| | - N He
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
| | - Z An
- Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
| | - R Yu
- Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
| | - C Li
- Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
| | - Y Li
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
| | - Y Li
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
| | - X Liu
- Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
| | - X Fang
- Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China
| | - J Zhao
- Department of Rheumatology and Immunology, Peking University Third Hospital, Beijing, China
| |
Collapse
|
37
|
Jiang J, Riquelme M, An Z, Zhang N, Xiong W, Zhang Y, Wang C. New antibody therapeutics targeting connexin hemichannels in treatment of osteosarcoma and breast cancer bone metastasis. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)31221-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Li Z, Chen Q, Feng L, Rodewald L, Xia Y, Yu H, Zhang R, An Z, Yin W, Chen W, Qin Y, Peng Z, Zhang T, Ni D, Cui J, Wang Q, Yang X, Zhang M, Ren X, Wu D, Sun X, Li Y, Zhou L, Qi X, Song T, Gao GF, Feng Z. Active case finding with case management: the key to tackling the COVID-19 pandemic. Lancet 2020; 396:63-70. [PMID: 32505220 PMCID: PMC7272157 DOI: 10.1016/s0140-6736(20)31278-2] [Citation(s) in RCA: 196] [Impact Index Per Article: 49.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2020] [Revised: 05/21/2020] [Accepted: 05/21/2020] [Indexed: 12/15/2022]
Abstract
COVID-19 was declared a pandemic by WHO on March 11, 2020, the first non-influenza pandemic, affecting more than 200 countries and areas, with more than 5·9 million cases by May 31, 2020. Countries have developed strategies to deal with the COVID-19 pandemic that fit their epidemiological situations, capacities, and values. We describe China's strategies for prevention and control of COVID-19 (containment and suppression) and their application, from the perspective of the COVID-19 experience to date in China. Although China has contained severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and nearly stopped indigenous transmission, a strong suppression effort must continue to prevent re-establishment of community transmission from importation-related cases. We believe that case finding and management, with identification and quarantine of close contacts, are vitally important containment measures and are essential in China's pathway forward. We describe the next steps planned in China that follow the containment effort. We believe that sharing countries' experiences will help the global community manage the COVID-19 pandemic by identifying what works in the struggle against SARS-CoV-2.
Collapse
Affiliation(s)
- Zhongjie Li
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qiulan Chen
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Luzhao Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yinyin Xia
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hailiang Yu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ruochen Zhang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wenwu Yin
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wei Chen
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ying Qin
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhibin Peng
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ting Zhang
- Weifang Medical University, Weifang, China
| | - Daxin Ni
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jinzhao Cui
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Qing Wang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaokun Yang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Muli Zhang
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiang Ren
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaojin Sun
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yuanqiu Li
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Zhou
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xiaopeng Qi
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Tie Song
- Guangdong Provincial Center for Disease Control and Prevention, Guangzhou, China
| | - George F Gao
- Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Zijian Feng
- Chinese Center for Disease Control and Prevention, Beijing, China
| |
Collapse
|
39
|
He H, Wang Y, Deng X, Yue C, Tang X, Li Y, Liu Y, Yin Z, Zhang G, Chen Z, Xie S, Wen N, An Z, Chen Z, Wang H. Immunogenicity of three sequential schedules with Sabin inactivated poliovirus vaccine and bivalent oral poliovirus vaccine in Zhejiang, China: an open-label, randomised, controlled trial. Lancet Infect Dis 2020; 20:1071-1079. [PMID: 32442523 DOI: 10.1016/s1473-3099(19)30738-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/04/2019] [Revised: 09/25/2019] [Accepted: 12/02/2019] [Indexed: 01/12/2023]
Abstract
BACKGROUND The globally synchronised introduction of inactivated poliovirus vaccine (IPV) and replacement of trivalent oral poliovirus vaccine (OPV) with bivalent OPV (bOPV) were successfully implemented in China's routine immunisation programme in May, 2016. In response to the global shortage of Salk-strain IPV, Sabin-strain IPV production was encouraged to develop and use in low-income and middle-income countries. We assessed the immunogenicity of the current routine poliovirus vaccination schedule in China and compared it with alternative schedules that use Sabin-strain IPV (sIPV) and bOPV. METHODS This open-label, randomised, controlled trial recruited healthy infants aged 60-75 days from two centres in Zhejiang, China. Eligible infants were full-term, due for their first polio vaccination, weighed more than 2·5 kg at birth, were healthy on physical examination with no obvious medical conditions, and had no contraindications to vaccination. Infants were randomly assigned (1:1:1) using permuted block randomisation (block size of 12) to one of three polio vaccination schedules, with the first, second, and third doses given at ages 2 months, 3 months, and 4 months, respectively: sIPV-bOPV-bOPV (1sIPV+2bOPV group; current regimen), sIPV-sIPV-bOPV (2sIPV+1bOPV group), or sIPV-sIPV-sIPV (3sIPV group). The primary endpoint was the proportion of infants with seroconversion to each of the three poliovirus serotypes 1 month after the third dose. Serious and medically important adverse events were monitored for up to 30 days after each vaccination. We assessed immunity in the per-protocol population (all children who completed all three vaccinations and had pre-vaccination and post-vaccination laboratory data) and safety in all children who received at least one dose of study vaccine. This trial is registered with Clinicaltrials.gov, NCT03147560. RESULTS Between May 1, 2016, and Dec 1, 2017, we enrolled and randomly assigned 528 eligible infants to one of the three treatment groups (176 in each group); 473 infants (158 in the 1sIPV+2bOPV group, 152 in the 2sIPV+1bOPV group, and 163 in the 3sIPV group) were included in the per-protocol population. 100% seroconversion against poliovirus types 1 and 3 was observed in all three groups. Infants who received an immunisation schedule containing bOPV had significantly higher antibody titres against poliovirus types 1 and 3 than did the sIPV-only group (2048 in all three treatment groups; p<0·0001). Seroconversion against type 2 poliovirus was observed in 98 (62%) infants in the 1sIPV+2bOPV group, 145 (95%) infants in the 2sIPV+1bOPV group, and 161 (99%) infants in the 3sIPV group. No serious adverse events occurred during the study; 14 minor, transient adverse events were observed, with no significant differences across study groups. INTERPRETATION All three study schedules were well tolerated and highly immunogenic against poliovirus types 1 and 3. Schedules containing two or three sIPV doses had higher seroconversion rates against poliovirus type 2 than did the schedule with a single dose of sIPV. Our findings support inclusion of two sIPV doses in the routine poliovirus vaccination schedule in China to provide better protection against poliovirus type 2 than provided by the current regimen. FUNDING Chinese Center for Disease Control and Prevention and China National Biotec Group Company.
Collapse
Affiliation(s)
- Hanqing He
- Immunisation Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Yamin Wang
- National Immunisation Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xuan Deng
- Immunisation Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Chenyan Yue
- National Immunisation Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Xuewen Tang
- Immunisation Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Yan Li
- National Immunisation Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yan Liu
- Immunisation Programme Department, Hangzhou Municipal Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Zhiying Yin
- Immunisation Programme Department, Quzhou Municipal Center for Disease Control and Prevention, Quzhou, Zhejiang, China
| | - Guoping Zhang
- Immunisation Programme Department, Chun'an County Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Zhongbing Chen
- Immunisation Programme Department, Longyou County Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Shuyun Xie
- Immunisation Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China
| | - Ning Wen
- National Immunisation Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunisation Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhiping Chen
- Immunisation Programme Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, China.
| | - Huaqing Wang
- National Immunisation Programme, Chinese Center for Disease Control and Prevention, Beijing, China.
| |
Collapse
|
40
|
Ma C, Hao L, Rodewald L, An Q, Wannemuehler KA, Su Q, An Z, Quick L, Liu Y, Yan R, Liu X, Zhang Y, Yu W, Zhang X, Wang H, Cairns L, Luo H, Gregory CJ. Risk factors for measles virus infection and susceptibility in persons aged 15 years and older in China: A multi-site case-control study, 2012–2013. Vaccine 2020; 38:3210-3217. [PMID: 32173094 PMCID: PMC10375840 DOI: 10.1016/j.vaccine.2020.03.006] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2019] [Revised: 01/28/2020] [Accepted: 03/01/2020] [Indexed: 10/24/2022]
Abstract
INTRODUCTION Endemic measles persists in China, despite >95% reported coverage of two measles-containing vaccine doses and nationwide campaign that vaccinated >100 million children in 2010. An increasing proportion of infections now occur among adults and there is concern that persistent susceptibility in adults is an obstacle to measles elimination in China. We performed a case-control study in six Chinese provinces between January 2012 to June 2013 to identify risk factors for measles virus infection and susceptibility among adults. METHODS Persons ≥15 years old with laboratory-confirmed measles were age and neighborhood matched with three controls. Controls had blood specimens collected to determine their measles IgG serostatus. We interviewed case-patients and controls about potential risk factors for measles virus infection and susceptibility. Unadjusted and adjusted matched odds ratios and 95% confidence intervals (CIs) were calculated via conditional logistic regression. We calculated attributable fractions for infection for risk factors that could be interpreted as causal. RESULTS 899 cases and 2498 controls were enrolled. Among controls, 165 (6.6%) were seronegative for measles IgG indicating persistent susceptibility to infection. In multivariable analysis, hospital visit and travel outside the prefecture in the prior 1-3 weeks were significant risk factors for measles virus infection. Occupation and reluctance to accept measles vaccination were significant risk factors for measles susceptibility. The calculated attributable fraction of measles cases from hospital visitation was 28.6% (95% CI: 20.6-38.8%). CONCLUSIONS Exposure to a healthcare facility was the largest risk factor for measles virus infection in adults in China. Improved adherence to hospital infection control practices could reduce risk of ongoing measles virus transmission and increase the likelihood of achieving and sustaining measles elimination in China. The use of control groups stratified by serological status identified distinct risk factors for measles virus infection and susceptibility among adults.
Collapse
|
41
|
Chen J, Liu X, Fu S, An Z, Feng Y, Wang R, Ji P. Effects of sophorolipids on fungal and oomycete pathogens in relation to pH solubility. J Appl Microbiol 2020; 128:1754-1763. [PMID: 31995843 DOI: 10.1111/jam.14594] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2019] [Revised: 12/30/2019] [Accepted: 01/17/2020] [Indexed: 11/28/2022]
Abstract
AIMS The objective of this study was to determine the effects of sophorolipids on several fungal and oomycete plant pathogens and the relationship between sophorolipids at different pH and antimicrobial activities. METHODS AND RESULTS Sophorolipids had different solubility at different pH with a dramatic increase in solubility when pH was 6 or higher. Inhibition of mycelial growth of Phytophthora infestans by sophorolipids was affected by pH values, showing that when the pH value was higher, the inhibition rate was lower. Sophorolipids inhibited spore germination and mycelial growth of several fungal and oomycete pathogens in vitro including Fusarium sp., F. oxysporum, F. concentricum, Pythium ultimum, Pyricularia oryzae, Rhizoctorzia solani, Alternaria kikuchiana, Gaeumannomyces graminis var. tritici and P. infestans and caused morphological changes in hyphae by microscope observation. Sophorolipids reduced β-1,3-glucanase activity in mycelia of P. infestans. In greenhouse studies, foliar application of sophorolipids at 3 mg ml-1 reduced severity of late blight of potato caused by P. infestans significantly. CONCLUSION Sophorolipids influenced spore germination and hyphal tip growth of several plant pathogens and pH solubility of sophorolipids had an effect on their efficacy. Application of sophorolipids reduced late blight disease on potato under greenhouse conditions. SIGNIFICANCE AND IMPACT OF THE STUDY The findings indicated that sophorolipids have the potential to be developed as a convenient and easy-to-use formulation for managing plant diseases.
Collapse
Affiliation(s)
- J Chen
- State Key Laboratory of Biobased Material and Green Papermaking, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.,Shandong Provincial Key Lab of Microbial Engineering, Department of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.,Department of Plant Pathology, University of Georgia, Tifton, GA, USA
| | - X Liu
- State Key Laboratory of Biobased Material and Green Papermaking, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.,Shandong Provincial Key Lab of Microbial Engineering, Department of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China
| | - S Fu
- State Key Laboratory of Biobased Material and Green Papermaking, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.,Shandong Provincial Key Lab of Microbial Engineering, Department of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China
| | - Z An
- State Key Laboratory of Biobased Material and Green Papermaking, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.,Shandong Provincial Key Lab of Microbial Engineering, Department of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China
| | - Y Feng
- State Key Laboratory of Biobased Material and Green Papermaking, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.,Shandong Provincial Key Lab of Microbial Engineering, Department of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China
| | - R Wang
- State Key Laboratory of Biobased Material and Green Papermaking, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China.,Shandong Provincial Key Lab of Microbial Engineering, Department of Bioengineering, Qilu University of Technology, Shandong Academy of Sciences, Jinan, China
| | - P Ji
- Department of Plant Pathology, University of Georgia, Tifton, GA, USA
| |
Collapse
|
42
|
Zhou J, Wen N, Zhang Y, Qi Q, Fan C, Yan D, Zhu X, Hao L, Zhu S, Liu Y, Ma X, Ma C, Nan L, Chen Y, Ma Q, Wang C, Deng K, Cao L, Shao G, Ding X, Yang H, An Z, E. Rodewald L, Xu A, Wang H, Feng Z, Yin Z, Wu X, Xu W. Detection and Initial Response to a Type 2 Vaccine-Derived Poliovirus — Sichuan Province, China, 2019. China CDC Wkly 2020. [DOI: 10.46234/ccdcw2020.045] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Yu W, Li Y, Wu J, Wang F, Wen N, Rodewald L, Hao L, Li Y, Zheng H, Li K, Ma C, Wu D, Cao L, Cao L, Ye J, Liu Y, Zhang G, Du W, An Z, Wang H, Yin Z. Vaccination Guidelines During and After the COVID-19 Epidemic in China. China CDC Wkly 2020; 2:661-665. [PMID: 34594733 PMCID: PMC8422244 DOI: 10.46234/ccdcw2020.169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2020] [Accepted: 06/03/2020] [Indexed: 11/14/2022] Open
Affiliation(s)
- Wenzhou Yu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yuanqiu Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jing Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ning Wen
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lixin Hao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yixing Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Keli Li
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Chao Ma
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Dan Wu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lei Cao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lingsheng Cao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jiakai Ye
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yanmin Liu
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Guomin Zhang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Wen Du
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- Zundong Yin,
| |
Collapse
|
44
|
Sun X, Wang F, Zhang G, Zheng H, Miao N, Yin Z, An Z. Progress Towards Hepatitis A Control and Prevention Through 2019: the National Immunization Program of China. China CDC Wkly 2020; 2:591-595. [PMID: 34594715 PMCID: PMC8428428 DOI: 10.46234/ccdcw2020.158] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2020] [Accepted: 07/26/2020] [Indexed: 11/24/2022] Open
Affiliation(s)
- Xiaojin Sun
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Fuzhen Wang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Guomin Zhang
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Hui Zheng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Ning Miao
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
- Zhijie An,
| |
Collapse
|
45
|
Ma C, Rodewald L, An Z, Yin Z, Feng Z. The National Immunization Advisory Committee in China: Roles of National Experts in Making Evidence-Based Recommendations for Immunization. China CDC Wkly 2019; 1:28-30. [PMID: 34594597 PMCID: PMC8428415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2019] [Accepted: 12/04/2019] [Indexed: 11/05/2022] Open
Affiliation(s)
- Chao Ma
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Lance Rodewald
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zhijie An
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zundong Yin
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China,Zundong Yin,
| | - Zijian Feng
- National Immunization Program, Chinese Center for Disease Control and Prevention, Beijing, China,Zijian Feng,
| |
Collapse
|
46
|
Park W, An Z. Radiobiological Difference Between Flattening Filter Free (FFF) Vs. Flattening Filter (FF) X-Ray Beams in Lung Cancer Cells. Int J Radiat Oncol Biol Phys 2019. [DOI: 10.1016/j.ijrobp.2019.06.1101] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
47
|
Chen Y, Song XT, Yao YM, Huang L, An Z, Yuan J, Xiong B, Liu YH, Zhang YQ. [Mortality and influencing factors on injecting drug users with HIV/AIDS in Guizhou province, 1996-2015]. Zhonghua Liu Xing Bing Xue Za Zhi 2019; 40:765-769. [PMID: 31357795 DOI: 10.3760/cma.j.issn.0254-6450.2019.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To understand the mortality and influencing factors on injecting drug users (IDUs) with HIV/AIDS, in Guizhou province, 1996-2015. Methods: A retrospective cohort study was conducted on IDUs with HIV/AIDS that were reported through national comprehensive HIV/AIDS information system, in Guizhou province during 1996-2015. Cox proportional hazard regression model was used to analyze the influencing factors on the mortality of HIV/AIDS. Results: A total of 3 958 cases of IDUs with HIV/AIDS were recruited in this study, with all-cause mortality rate of 44.01% (1 742/3 958) and total mortality rate of 7.80/100 person-years, respectively. The median survival time between diagnosis and death was 8.08 years. Mortality rate was 3.57/100 person-years in the group receiving antiretroviral therapy (ART). The mortality appeared to be 4.08/100 person-years in the group who were on methadone maintenance treatment (MMT). Data from the multiple regression analysis indicated that factors of gender, ethnicity, age when HIV/AIDS diagnosis was made, CD(4)(+)T lymphocyte (CD(4)) count at the first testing, ART and MMT were significantly associated with deaths among these people. The risk of death in females was 0.82 times (95%CI: 0.69-0.98) higher than that in males. The risk of deaths among the ethnic minority subjects was 1.39 times (95%CI: 1.21-1.60) higher than that of the Hans. The risk of death appeared to be 2.44 times higher (95%CI: 1.07-5.56) in the over-50-year of age group than in the <20 year-old group, when HIV/AIDS was diagnosed for the first time. The risk of death in CD(4) ≥500/μl group in the first time was 0.27 times (95%CI: 0.22-0.32) more than CD(4) <200/μl group in the firs time. The risk of death in cases who were treated with ART or MMT was 2.83 times (95%CI: 2.45-3.26) and 1.35 times (95%CI: 1.15-1.59) higher than those who did not receive any treatment, respectively. Conclusion: Higher risks on death seemed to be related to the following factors: being male, older age at the time of diagnosis, lower CD(4) at diagnosis, not on ART or MMT among the IDUs with HIV/AIDS in Guizhou province, between 1996-2015.
Collapse
Affiliation(s)
- Y Chen
- Guizhou Provincial Center for Disease Control and Prevention, Guiyang 550001, China
| | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Wang X, An Z, Huo D, Jia L, Li J, Yang Y, Liang Z, Wang Q, Wang H. Enterovirus A71 vaccine effectiveness in preventing enterovirus A71 infection among medically-attended hand, foot, and mouth disease cases, Beijing, China. Hum Vaccin Immunother 2019; 15:1183-1190. [PMID: 30779680 PMCID: PMC6605830 DOI: 10.1080/21645515.2019.1581539] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Introduction: Enterovirus A71(EV-A71)-associated hand, foot, and mouth disease (HFMD) has been reported worldwide, and poses a particularly heavy burden on patients, families, and society in China. Three Chinese companies have licensed inactivated EV-A71 vaccines, all of which have demonstrated good efficacy for preventing EV-A71-associated disease in clinical trials. However, real-world performance of EV-A71 vaccine has not been evaluated. Methods: We used a test-negative design case-control study to estimate vaccine effectiveness (VE) against medically attended EV-A71-associated HFMD. Subjects were children 5 years of age and under who had been in health facilities participating in the HFMD case and virologic surveillance platforms in Beijing. Enterovirus infections were laboratory confirmed, and EV-A71 vaccination status was extracted from electronic immunization records. Children testing positive for EV-A71 were cases; controls were children testing negative for EV-A71 infection. Logistic regression was used to estimate VE. We assessed sensitivity of VE estimates to control group inclusion criteria by repeating the regression analyses with two alternative control groups. Results: A total of 2,184 HFMD patients aged 5 years and under were enrolled in the study; 24 were severe, and 2,160 were mild. For severe cases, two-dose VE estimate was 100% (95% CI: −68.1%, 100%). For mild cases, 1-dose and 2-dose adjusted VE estimates were 69.8% and 83.7%, respectively. Two-dose VE estimates varied by less than 4 percentage points regardless of control group definition. Conclusions: Our findings suggested the vaccines performed well in the real world for children 5 years of age and under in Beijing, China.
Collapse
Affiliation(s)
- Xiaoli Wang
- a Department of the National Immunization Program , Chinese Center for Disease Control and Prevention , Beijing , China.,b Beijing Center for Disease Prevention and Control , Beijing Research Center for Preventive Medicine , Beijing , China
| | - Zhijie An
- a Department of the National Immunization Program , Chinese Center for Disease Control and Prevention , Beijing , China
| | - Da Huo
- b Beijing Center for Disease Prevention and Control , Beijing Research Center for Preventive Medicine , Beijing , China
| | - Lei Jia
- b Beijing Center for Disease Prevention and Control , Beijing Research Center for Preventive Medicine , Beijing , China
| | - Jie Li
- b Beijing Center for Disease Prevention and Control , Beijing Research Center for Preventive Medicine , Beijing , China
| | - Yang Yang
- b Beijing Center for Disease Prevention and Control , Beijing Research Center for Preventive Medicine , Beijing , China
| | - Zhichao Liang
- b Beijing Center for Disease Prevention and Control , Beijing Research Center for Preventive Medicine , Beijing , China
| | - Quanyi Wang
- b Beijing Center for Disease Prevention and Control , Beijing Research Center for Preventive Medicine , Beijing , China
| | - Huaqing Wang
- a Department of the National Immunization Program , Chinese Center for Disease Control and Prevention , Beijing , China
| |
Collapse
|
49
|
Li Y, Chu SY, Yue C, Wannemuehler K, Xie S, Zhang F, Wang Y, Zhang Y, Ma R, Li Y, Zuo Z, Rodewald L, Xiao Q, Feng Z, Wang H, An Z. Immunogenicity and safety of measles-rubella vaccine co-administered with attenuated Japanese encephalitis SA 14-14-2 vaccine in infants aged 8 months in China: a non-inferiority randomised controlled trial. Lancet Infect Dis 2019; 19:402-409. [PMID: 30833160 DOI: 10.1016/s1473-3099(18)30650-9] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Revised: 10/02/2018] [Accepted: 10/17/2018] [Indexed: 10/27/2022]
Abstract
BACKGROUND In China, measles-rubella vaccine and live attenuated SA 14-14-2 Japanese encephalitis vaccine (LJEV) are recommended for simultaneous administration at 8 months of age, which is the youngest recommended age for these vaccines worldwide. We aimed to assess the effect of the co-administration of these vaccines at 8 months of age on the immunogenicity of measles-rubella vaccine. METHODS We did a multicentre, open-label, non-inferiority, two-group randomised controlled trial in eight counties or districts in China. We recruited healthy infants aged 8 months who had received all scheduled vaccinations according to the national immunisation recommendations and who lived in the county of the study site. Enrolled infants were randomly assigned (1:1) to receive either measles-rubella vaccine and LJEV simultaneously (measles-rubella plus LJEV group) or measles-rubella vaccine alone (measles-rubella group). The primary outcome was the proportion of infants with IgG antibody seroconversion for measles 6 weeks after vaccination, and a secondary outcome was the proportion of infants with IgG antibody seroconversion for rubella 6 weeks after vaccination. Analyses included all infants who completed the study. We used a 5% margin to establish non-inferiority. This trial was registered at ClinicalTrials.gov (NCT02643433). FINDINGS 1173 infants were assessed for eligibility between Aug 13, 2015, and June 10, 2016. Of 1093 (93%) enrolled infants, 545 were randomly assigned to the measles-rubella plus LJEV group and 548 to the measles-rubella group. Of the infants assigned to each group, 507 in the measles-rubella plus LJEV group and 506 in the measles-rubella group completed the study. Before vaccination, six (1%) of 507 infants in the measles-rubella plus LJEV group and one (<1%) of 506 in the measles-rubella group were seropositive for measles; eight (2%) infants in the measles-rubella plus LJEV group and two (<1%) in the measles-rubella group were seropositive for rubella. 6 weeks after vaccination, measles seroconversion in the measles-rubella plus LJEV group (496 [98%] of 507) was non-inferior to that in the measles-rubella group (499 [99%] of 506; difference -0·8% [90% CI -2·6 to 1·1]) and rubella seroconversion in the measles-rubella plus LJEV group (478 [94%] of 507) was non-inferior to that in the measles-rubella group (473 [94%] of 506 infants; difference 0·8% [90% CI -1·8 to 3·4]). There were no serious adverse events in either group and no evidence of a difference between the two groups in the prevalence of any local adverse event (redness, rashes, and pain) or systemic adverse event (fever, allergy, respiratory infections, diarrhoea, and vomiting). Fever was the most common adverse event (97 [19%] of 507 infants in the measles-rubella plus LJEV group; 108 [21%] of 506 infants in the measles-rubella group). INTERPRETATION The evidence of similar seroconversion and safety with co-administered LJEV and measles-rubella vaccines supports the co-administration of these vaccines to infants aged 8 months. These results will be important for measles and rubella elimination and the expansion of Japanese encephalitis vaccination in countries where it is endemic. FUNDING US Centers for Disease Control and Prevention, US Department of Health and Human Services; China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases.
Collapse
Affiliation(s)
- Yan Li
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China; Immunization Program Department, Lishui Prefectural Center for Disease Control and Prevention, Lishui, China
| | - Susan Y Chu
- Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Chenyan Yue
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Kathleen Wannemuehler
- Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Shuyun Xie
- Immunization Program Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China
| | - Fubin Zhang
- Immunization Program Department, Hebei Provincial Center for Disease Control and Prevention, Shijiazhuang, China
| | - Yamin Wang
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Yuxi Zhang
- Immunization Program Department, Baoding Prefectural Center for Disease Control and Prevention, Baoding, China
| | - Rui Ma
- Immunization Program Department, Ningbo Prefectural Center for Disease Control and Prevention, Ningbo, China
| | - Yumin Li
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China; Immunization Program Department, Lishui Prefectural Center for Disease Control and Prevention, Lishui, China
| | - Zhiping Zuo
- Immunization Program Department, Baoding Prefectural Center for Disease Control and Prevention, Baoding, China
| | - Lance Rodewald
- Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, USA
| | - Qiyou Xiao
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Zijian Feng
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China
| | - Huaqing Wang
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.
| | - Zhijie An
- National Immunization Programme, Chinese Center for Disease Control and Prevention, Beijing, China.
| |
Collapse
|
50
|
An Z, Gao J, Wang J. A New Heterometallic Pb(II)–Ca(II) Coordination Polymer with 2D Pb–O–Ca Inorganic Connectivity. RUSS J COORD CHEM+ 2019. [DOI: 10.1134/s1070328418120011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|